document incorporate reference part ii iii portion registrant annual report shareholder fiscal year annual report part iii portion registrant proxy statement annual meeting shareholder file day close registrant fiscal year proxy statementitem business general segment business geographic area raw material patent trademark seasonality competition research development environment regulation available information risk factor b unresolved staff comment property legal proceeding safety disclosure executive officer registrant ii market registrant common equity relate stockholder matter issuer purchase equity security select financial datum management discussion analysis financial condition result operation quantitative qualitative disclosure market risk financial statement supplementary data change disagreement accountant account financial disclosure control procedure b information iii director executive officer corporate governance executive compensation security ownership certain beneficial owner management relate stockholder matter certain relationship relate transaction director independence principal accountant fee service iv exhibit financial statement schedule schedule ii valuation qualifying account signature report independent register public accounting firm financial statement schedule exhibit index table content item business general johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product health care field johnson johnson hold company operate company conduct business virtually country world company primary focus product relate human health wellbee johnson johnson incorporate state new jersey companys structure base principle decentralize management executive committee johnson johnson principal management group responsible strategic operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device diagnostic business segment line principle decentralize management senior management group international operating company responsible strategic plan daytoday operation company subsidiary business segment exception manage citizen country locate segment business company organize business segment consumer pharmaceutical medical device diagnostic additional information require item incorporate reference narrative tabular description segment operate result caption management discussion analysis result operation financial condition note segment business geographic area note consolidated financial statement annual report file exhibit report consumer consumer segment include broad range product baby care skin care oral care wound care womens health care field nutritional overthecounter pharmaceutical product wellness prevention platform baby care franchise include johnson baby line product major brand skin care franchise include aveeno clean clear johnson adult neutrogena roc lubriderm dabao vendme product line brand oral care franchise include listerine rembrandt oral care line reach interdental product wound care franchise include bandaid brand adhesive bandage neosporin aid product major brand women health franchise carefree pantiliner ob tampon stayfree sanitary protection product principal nutritional line splenda calorie sweetener overthecounter medicine include broad family tylenol acetaminophen product sudafe cold flu allergy product zyrtec allergy product motrin ib ibuprofen product pepcid ac acid controller product market general public sell retail outlet distributor world pharmaceutical pharmaceutical segment include product follow area antiinfective antipsychotic contraceptive gastrointestinal hematology immunology infectious disease neurology oncology pain management thrombosis vaccine product distribute directly retailer wholesaler health care professional prescription use key product pharmaceutical segment include remicade infliximab treatment number immunemediate inflammatory disease stelara ustekinumab treatment adult moderate severe plaque psoriasis simponi golimumab treatment adult moderate severe rheumatoid arthritis active psoriatic arthritis active ankylose spondylitis velcade bortezomib treatment multiple myeloma zytiga abiraterone acetate treatment metastatic castrationresistant prostate cancer prezista darunavir intelence etravirine edurant rilpivirine treatment hivaid incivo telaprevir treatment hepatitis c nucynta er tapentadol extend release tablet treatment moderate severe chronic pain adult neuropathic pain associate diabetic peripheral neuropathy adult invega sustenna paliperidone palmitate acute maintenance treatment schizophrenia adult invega paliperidone extendedrelease tablet treatment schizophrenia schizoaffective disorder risperdal consta risperidone treatment management bipolar disorder schizophrenia xarelto rivaroxaban oral anticoagulant prevention thrombosis follow total hip knee replacement surgery prevention stroke patient atrial fibrillation treatment pulmonary embolism pe deep vein thrombosis dvt reduce risk recurrence dvt pe follow initial month treatment acute venous thromboembolism procrit epoetin alfa sell outside eprex stimulate red blood cell production levaquin levofloxacin treatment bacterial infectionstable content concerta methylphenidate hcl extendedrelease tablet cii treatment attention deficit hyperactivity disorder aciphexpariet proton pump inhibitor comarketed eisai inc duragesic fentanyl transdermal system cii sell outside durogesic treatment chronic pain offer novel delivery system medical device diagnostic medical device diagnostic segment include broad range product principally professional field physician nurse hospital clinic include product treat cardiovascular disease orthopaedic neurological product blood glucose monitor insulin delivery product general surgery biosurgical energy product professional diagnostic product infection prevention product disposable contact lense product distribute wholesaler hospital retailer directly surgical supply distributor geographic area business johnson johnson conduct operate company locate country include united states sell product virtually country world product sell international business include describe segment business consumer pharmaceutical medical device diagnostic principal market product method distribution international business vary country culture product sell international business include develop united states develop subsidiary abroad investment activity country outside united states subject high risk comparable activity investment commercial climate influence restrictive economic policy political uncertainty raw material raw material essential company business generally readily available multiple source exception temporary unavailability raw material likely material adverse effect financial result company patent trademark company subsidiary practice obtain patent protection product process possible licensed number patent relate product manufacturing process aggregate believe material importance company operation business sale company large product remicade infliximab account approximately company total revenue fiscal accordingly patent relate product believe material company june levaquin lose market exclusivity subject generic competition united states sales levaquin united states decline approximately compare company subsidiary practice sell product trademark obtain protection trademark available mean trademark protect registration united states country product market company consider trademark aggregate material importance operation business seasonality worldwide sale reflect significant degree seasonality spend heavy fourth quarter year quarter reflect increase spending decision principally advertise research development activity competition product line company subsidiary compete company locally globally world competition exist product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new innovative product important company success area business include protect company portfolio intellectual property competitive environment require substantial investment continue research maintain sale force addition development maintenance customer demand company consumer product involve significant expenditure advertising promotion table content research development research activity represent significant company business research development expenditure relate process discover testing develop new product improve exist product demonstrate product efficacy regulatory compliance prior launch company remain committed invest research development aim deliver high quality innovative product worldwide cost research development activity amount billion billion billion fiscal year respectively major research facility locate united states belgium brazil canada china france germany india israel japan netherlands singapore switzerland united kingdom environment company subject variety international environmental protection measure company believe operation comply material respect applicable environmental law regulation companys compliance requirement past year expect material effect capital expenditure cash flow earning competitive position regulation company business subject vary degree governmental regulation country operation conduct general trend increasingly stringent regulation united states drug device diagnostic cosmetic industry long subject regulation federal state agency primarily product safety efficacy manufacturing advertising labeling safety report exercise broad regulatory power food drug administration fda continue result increase amount test documentation require fda clearance new drug device correspond increase expense product introduction similar trend evident major market outside united states cost human health care continue subject study investigation regulation governmental agency legislative body world united states attention focus drug price profit program encourage doctor write prescription particular drug recommend use purchase particular medical device payer potent force market place increase attention pay drug medical device price appropriate drug medical device utilization quality cost health care follow supreme court decision june uphold patient protection affordable care act aca increase pace regulatory issuance government agency designate carry extensive requirement aca positive negative impact healthcare industry remain uncertain provision aca ultimately affect industry regulatory agency purview company operate administrative power subject action product withdrawal recall seizure product civil criminal sanction case company subsidiary deem advisable initiate product recall addition business practice health care industry come increase scrutiny particularly united states government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty available information company main corporate website address wwwjnjcom copy company quarterly report form q annual report current report form k file furnish securities exchange commission sec amendment foregoing provide charge shareholder submit write request secretary principal executive office company call company sec filing available company website wwwinvestorjnjcomgovernancematerialscfm soon reasonably practicable electronically file furnish sec sec filing available secs website wwwsecgov addition write charter audit committee compensation benefit committee nominate corporate governance committee regulatory compliance government affair committee science technology sustainability committee board director company principle corporate governance policy business conduct employee code business conduct ethic member board director executive officer corporate governance material available wwwinvestorjnjcomgovernancematerialscfm website address provide charge shareholder submit write request provide table content item risk factor important factor cause company actual result differ company expectation forwardlooke statement report set forth exhibit report item b unresolved staff comment applicable item property company subsidiary operate manufacturing facility occupy approximately million square foot floor space manufacturing facility industry segment company business approximately follow square foot segment thousand consumer pharmaceutical medical device diagnostic worldwide total united states facility consumer segment pharmaceutical segment medical device diagnostic segment company manufacture operation outside united states conduct facility serve business segment location manufacture facility major geographic area world follow square foot geographic area number facility thousands united states europe western hemisphere exclude africa asia pacific worldwide total addition manufacture facility discuss johnson johnson subsidiary maintain numerous office warehouse facility world research facility discuss item business research development company subsidiary generally seek manufacture facility principally location abroad lease office warehouse facility lease company commit maintain property good operating condition repair facility utilize mcneilppc inc continue operate consent decree sign fda govern certain mcneil consumer healthcare manufacturing operation mcneilppc inc continue operate manufacturing facility las piedras puerto rico lancaster pennsylvania production volume facility continue impact additional review approval process require consent decree company expect continue plant operate consent decree produce simplify portfolio focus key brand fort washington pennsylvania manufacturing site operation time mcneil continue work resite product previously produce fort washington facility facility discussion matter find head government proceeding mcneil consumer healthcare note legal proceeding note consolidated financial statement annual report file exhibit report information lease obligation note rental expense lease commitment note consolidated financial statement annual report file exhibit report segment information addition property plant equipment contain note segment business geographic table content area note consolidated financial statement annual report file exhibit report item legal proceeding information set forth note legal proceeding note consolidated financial statement annual report incorporate reference file exhibit report addition johnson johnson subsidiaries time time party government investigation inspection proceeding relate environmental matter include compliance applicable environmental law connection routine inspection subsidiary manufacturing facility california department toxic substance control department allege violation regulation deal handle certain waste company believe adequate defense allegation exist presently discussion department validity allegation company predict ultimate outcome proceeding bring matter company expect matter resolve significant penalty adverse impact company item safety disclosure applicable executive officer registrant list executive officer company february indicate employee company hold position indicate past year family relationship executive officer arrangement understand executive officer person pursuant executive officer select annual meeting board director executive officer elect board hold office year respective successor elect qualified early resignation removal information regard director company include information alex gorsky incorporate reference material caption election director proxy statement age position dominic j caruso member executive committee vice president finance chief financial officera peter fasolo member executive committee vice president global human resources b alex gorsky chairman board directors chairman executive committee chief executive officer sandra e peterson member executive committee group worldwide chairmanc paulus stoffels member executive committee chief scientific officer worldwide chairman pharmaceutical groupd michael h ullmann member executive committee vice president general counsele mr j caruso join company company acquire centocor inc time acquisition senior vice president finance centocor mr caruso name vice president finance orthomcneil pharmaceutical inc subsidiary company vice president group finance company medical device diagnostic group mr caruso name vice president company group finance organization mr caruso member executive committee vice president finance chief financial officer b dr p fasolo join company vice president worldwide human resource cordis corporation subsidiary company name vice president global talent management company leave johnson johnson join kohlberg kravis roberts co chief talent officer dr fasolo return company september vice president global human resource january member executive committee c ms e peterson join company december group worldwide chairman member executive committee responsibility consumer group company johnson johnson supply chain information technology prior join johnson johnson ms peterson extensive global career healthcare consumer good consulting recently chairman chief executive officer bayer table content cropscience ag germany previously serve president chief executive officer bayer medical care president bayer healthcare ag diabetes care division join bayer ms peterson hold number leadership role medco health solution previously know merck medco responsibility application information technology healthcare system dr p stoffels join company acquisition virco tibotec chief executive officer virco chairman tibotec appoint company group chairman global virology lead development prezista intelence lead product treatment hiv assume role company group chairman pharmaceutical responsibility worldwide research development cns internal medicine franchise dr stoffels appoint global head research development pharmaceutical worldwide chairman pharmaceutical group responsibility research development business development global strategy innovation october dr stoffels appoint chief scientific officer member executive committee e mr h ullmann join company corporate attorney law department appoint corporate secretary serve role time hold management position law department name general counsel medical device diagnostic group mr ullmann appoint vice president general counsel member executive committee january ii item market registrant common equity relate stockholder matter issuer purchase equity security february record holder common stock company additional information call item incorporate reference material caption management discussion analysis result operation financial condition liquidity capital resource share repurchase dividend information common stock market price note common stock stock option plan stock compensation agreement note consolidated financial statement shareholder return performance graph support schedule annual report file exhibit report item security ownership certain beneficial owner management relate stockholder matter equity compensation plan information report issuer purchase equity security follow table provide information respect common stock purchase company fiscal fourth quarter pursuant accelerate stock repurchase agreement connection acquisition synthes inc company purchase common stock open market fiscal fourth quarter repurchase represent stockforstock option exercise settle fiscal fourth quarter maximum number total number share approximate dollar unit purchase value share publicly unit total number avg price announce plan purchase period share purchase pay share program plan programs october october october november november december total item select financial datum information call item incorporate reference summary operation statistical datum support schedule annual report file exhibit report item management discussion analysis financial condition result operation information call item incorporate reference narrative tabular material caption management discussion analysis result operation financial condition annual report file exhibit report table content item quantitative qualitative disclosure market risk information call item incorporate reference material caption management discussion analysis result operation financial condition liquidity capital resource finance market risk note summary significant accounting policy financial instrument note consolidated financial statement annual report file exhibit report item financial statement supplementary datum information call item incorporate reference audit consolidated financial statement note thereto material caption report independent register public accounting firm annual report file exhibit report item change disagreement accountant account financial disclosure applicable item control procedure disclosure control procedure end period cover report company evaluate effectiveness design operation disclosure control procedure company disclosure control procedure design ensure information require disclose company report file submit exchange act record process summarize report time period specify sec rule form disclosure control procedure include limitation control procedure design ensure information require disclose company report file submit exchange act accumulate communicate company management include principal executive principal financial officer person perform similar function appropriate allow timely decision require disclosure alex gorsky chairman chief executive officer dominic j caruso chief financial officer review participate evaluation base evaluation messr gorsky caruso conclude end period cover report company disclosure control procedure effective management report internal control financial reporting information call item incorporate reference material caption management report internal control financial report annual report file exhibit report change internal control financial reporting fiscal quarter end december change companys internal control financial reporting identify connection evaluation require rules exchange act materially affect reasonably likely materially affect company internal control financial reporting item b information applicable iii item director executive officer corporate governance information call item incorporate reference material caption item election director stock ownership section compliance section beneficial ownership report compliance discussion audit committee caption corporate governance standing board committee proxy statement material caption executive officer registrant report company policy business conduct cover employee include chief executive officer chief financial officer controller meet requirement sec rules promulgate section sarbanesoxley act policy business conduct available company website wwwinvestorjnjcomgovernancepoliciescfm copy available shareholder charge write request secretary company principal executive office substantive amendment policy business conduct waiver policy grant chief executive officer chief financial officer controller post company website wwwinvestorjnjcomgovernancecfm business day retain website year addition company adopt code business conduct ethic member board director executive officer code business conduct ethic member board director executive officer available table content company website wwwinvestorjnjcomgovernancepoliciescfm copy available shareholder charge write request secretary company principal executive office substantive amendment code waiver code grant member board director executive officer post company website wwwinvestorjnjcomgovernancecfm business day retain website year item executive compensation information call item incorporate reference material caption corporate governance item election director director compensation compensation committee report compensation discussion analysis executive compensation proxy statement material incorporate reference material caption compensation committee report proxy statement shall deem furnish file report shall deem incorporate reference filing security act amend securities exchange act amend result furnish extent registrant specifically incorporate reference item security ownership certain beneficial owner management relate stockholder matter additional information call item incorporate reference material caption stock ownership section compliance proxy statement note common stock stock option plan stock compensation agreement note consolidated financial statement annual report file exhibit report equity compensation plan information follow table provide certain information december concern share company common stock issue exist equity compensation plan number security issue weighted average number security exercise exercise price remain available outstanding option outstanding option future issuance equity plan category right right compensation plan equity compensation plan approve security holder equity compensation plan approve security holder total include category follow equity compensation plan approve company shareholder stock option plan longterm incentive plan longterm incentive plan include category share common stock company issuable equity compensation plan assume company acquisition scios inc time acquisition option acquire equity acquire company replace option acquire common stock company stock option equity award type plan assumption plan company stock option equity award type plan future share issue plan approve shareholder scio scios nonofficer stock option plan column exclude share reflect column number security issue exercise outstanding option right longterm incentive plan expire april option restrict share grant subsequent date longterm incentive plan item certain relationship relate transaction director independence information call item incorporate reference material caption transaction relate person corporate governance director independence proxy statement table content item principal accountant fee service information call item incorporate reference material caption ratification appointment independent register public accounting firm proxy statement iv item exhibit financial statement schedule follow document file report financial statement follow audit consolidated financial statement note thereto material caption report independent register public accounting firm annual report incorporate reference file exhibit report consolidated balance sheet end fiscal year consolidated statement earning fiscal year consolidate statement comprehensive income fiscal year consolidated statement equity fiscal year consolidated statement cash flow fiscal year note consolidated financial statement report independent register public accounting firm financial statement schedule schedule ii valuation qualifying account schedule list omit require applicable exhibit require file item l regulation sk information call item incorporate reference exhibit index report table content johnson johnson subsidiaries schedule ii valuation qualifying account fiscal year end december january january dollar millions balance balance beginning end period accrual paymentsother period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million million million december january january respectively table content signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize date february johnson johnson registrant gorsky gorsky chairman board director chief executive officer pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date gorsky chairman board director february gorsky chief executive officer director principal executive officer j caruso chief financial officer principal financial officer february j caruso j cosgrove controller principal accounting officer february j cosgrove coleman director february coleman j g cullen director february j g cullen e l davis director february e l davis e johns director february e johns table content signature title date l lindquist director february l lindquist mulcahy director february mulcahy l f mullin director february l f mullin w perez director february w perez c prince director february c prince satcher director february satcher e washington director february e washington r williams director february r williams table content report independent register public accounting firm financial statement schedule board directors johnson johnson audits consolidated financial statement effectiveness internal control financial reporting refer report date february appear annual report shareholder johnson johnson report consolidated financial statement incorporate reference annual report include audit financial statement schedule list item opinion financial statement schedule present fairly material respect information set forth read conjunction relate consolidated financial statement pricewaterhousecooper llp new york new york february table content exhibit index reg sk exhibit table description item exhibit ia restate certificate incorporation effective april incorporate reference exhibit registrant form k annual report year end december ib certificate amendment restate certificate incorporation company effective incorporate reference exhibit registrant annual report year end january ic certificate amendment restate certificate incorporation company effective incorporate reference exhibit aiii registrant annual report year end december d certificate amendment restate certificate incorporation company effective incorporate reference exhibit registrant form q quarterly report quarter end july ie certificate amendment restate certificate incorporation company effective april incorporate reference exhibit registrant form q quarterly report quarter end april ii bylaw company amend effective april incorporate reference exhibit registrant form k current report file april request security exchange commission registrant furnish copy instrument define right holder longterm debt registrant stock option plan nonemployee director incorporate reference exhibit registrant annual report year end december b stock option plan amend incorporate reference exhibit b registrant annual report year end january c longterm incentive plan incorporate reference exhibit registrant registration statement file commission file form restrict share nonemployee directors longterm incentive plan incorporate reference exhibit registrant form k current report file august e form stock option certificate restrict share unit certificate performance share unit certificate longterm incentive plan incorporate reference exhibit registrant form k current report file january f longterm incentive plan incorporate reference appendix registrant proxy statement file commission march g form stock option certificate restrict share unit certificate performance share unit certificate longterm incentive plan incorporate reference exhibit registrant form q quarterly report file h executive incentive plan amend incorporate reference exhibit f registrant annual report year end december domestic defer compensation certificate extra compensation plan incorporate reference exhibit g registrant annual report year end december j amendment certificate extra compensation plan effective january incorporate reference exhibit j registrant annual report year end december k certificate longterm performance plan incorporate reference exhibit registrant form q quarterly report quarter end september l amend restate deferred fee plan director incorporate reference exhibit k registrant annual report year end january executive income deferral plan amend restate incorporated reference exhibit registrant form q quarterly report quarter end september table content reg sk exhibit table description item exhibit n excess saving plan incorporate reference exhibit j registrant form k annual report year end december amendments johnson johnson excess saving plan effective january incorporate reference exhibit p registrant annual report year end december p excess benefit plan supplemental retirement plan incorporate reference exhibit h registrant annual report year end january q amendment excess benefit plan johnson johnson affiliate company effective january incorporate reference exhibit r registrant annual report year end december r executive life plan agreement incorporate reference exhibit registrant annual report year end january employment agreement dr paulus stoffels incorporate reference exhibit registrant form q quarterly report quarter end september summary employment arrangement sandra e peterson file document statement computation ratio earning fix charge file document follow section annual report shareholders fiscal year incorporate reference report deem file management discussion analysis result operation financial condition audit consolidated financial statement support schedule summary operation statistical datum support schedule shareholder return performance graph file document subsidiary file document consent independent register public accounting firm file document certification chief executive officer pursuant section sarbanesoxley act file document b certification chief financial officer pursuant section sarbanesoxley act file document certification chief executive officer pursuant section sarbanesoxley act furnish document b certification chief financial officer pursuant section sarbanesoxley act furnish document cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement file document xbrl extensible business report language follow material johnson johnsons annual report fiscal yearende december format extensive business report language xbrl consolidate balance sheet ii consolidated statement earning iii consolidated statement comprehensive income iv consolidate statement equity v consolidate statement cash flow vi note consolidated financial statement vii schedule ii valuation qualifying account management contract compensatory plan copy exhibit list provide charge shareholder submit write request specify desire exhibit secretary principal executive office company exhibit employment agreement johnson johnson co peter fasolo ww vicepresident human resource johnson johnson plaza new brunswick new jersey employer sandra e peterson old beach road tudor lodge newport rhode island employee employer employee hereinafter refer collectively party individually party employer corporation organize law state new jersey united states america wishes hire employee indefinite term b employee desire work employer party agree follow title job duty report relationship effective date employee shall employ employer shall title group worldwide chair serve executive committee member employer employee shall directly report chief executive officer ceo company employee shall responsible lead manage employer consumer supply chain business unit employer chief executive officer right assign duty responsibility employee commensurate employee title knowledge experience skill specify duty work location employee place work shall employer corporate office new brunswick new jersey employee duty require employee regularly travel business location united states abroad travel include reasonably require weekend public holiday employment term start date employment agreement atwill enter indefinite term anticipate day employment start date november early party agree provide employment agreement shall null void ab initio force effect employee unable obtain agreement current employer current employer allow early cancellation contract service agreement service agreement current employer unable release andor amendment post contractual noncompete obligation post employment restriction manner reasonably satisfactory employer manner permit commence employment consistent job responsibility dutie employment agreement party agree use reasonable effort negotiate employee departure current employer respect service agreement post employment restriction employer agree extend november start date december provide negotiation employee current employer condition set forth continue progressing provide employee start employment employer day precondition set forth meet later december employee agrees promptly inform employer current employer inform unwilling nego tiate provision andor negotiation current employer terminate impasse party agree offer employment employment agreement expire prior december remain open long employee commence employment date party mutually conclude current employer unwilling negotiate term legally permit employee commence employment employer consistent timing job responsibility duties employment agreement salary employee start base salary base salary shall applicable deduction shall payable biweekly consistent normal payroll practice employer employee consider merit increase base salary accordance employer normal cycle increase applicable shall employee base salary purpose employment agreement merit increase determined employer sole discretion base factor include market datum internal equity individual performance business performance signon bonus employee shall receive installment payment cash sign bonus totaling signon applicable withholding pay cash installment describe installment signon subject employee actively employ payout date installment payment pay employee shortly employee start date second payment pay april provide sentence paragraph subject employee remain actively employ employer date payout employee voluntarily terminate employment good reason disability define company disability plan employment terminate employer cause prior anniversary date second installment payment employee require reimburse employer signon installment payment employee receive unpaid installment payment signon payable terminate cause define resign good reason define cause purpose employment agreement shall mean occurence follow employee conviction plea guilty nolo contendere crime involve moral turpitude dishonesty fraud theft financial impropriety unethical business conduct felony nature whatsoever result incarceration criminal probation ii employee engagement conduct constitute gross misconduct gross neglect willful failure perform material duty employee position iii employee material breach applicable rule policy andor practice employer include limited conduct constitute group offense employer performance conduct standard policy violation employer policy business conduct iv employee material breach secrecy intellectual property noncompetition nonsolicitation agreement purpose agreement willful failure perform apply act ommission conduct employee good faith reasonable belief act omission good interest employer good reason purpose employment agreement mean occurrence follow employee consent material adverse change employee title dutie responsibility include report responsibility ii material reduction employee base salary iii relocation employee principal office mile office new brunswick new jersey apply customary business travel abroard associate role group worldwide chair require determined job duty section iv failure assign successor business contractual obligation employer employment agreement employer employee agree good reason shall exist employee provide employer write notice act allege constitute good reason ninety day employee knowledge occurrence event employer fail cure act thirty day receipt notice curable employee terminate employment day follow expiration cure period termination account good reason rsu replacement award employee shall receive new hire restrict share unit rsu grant fair value compensate award employee forfeit leave employment current employer number rsus determine divide rsu fair value fair value rsu employer common stock grant date define number rsus round near share employee new hire grant process grant date business day month day day follow start date provide event long employee start date later december award grant later december grant date shall subject administer accordance term employer ltip vest subject term accompany award agreement award agreement grant share vest equal installment follow vest year grant date vest year grant date vest year grant date employee understand agree active employee date vest vest rsu share severance year employment employer terminate employment agreement cause define section employee terminate employment good reason define section employee shall entitle cash lump sum severance payment severance equal week base salary applicable deduction employee receipt severance subject execution general release claim day termination date general release claim impose employee postemployment covenant employee agree prior termination employment continue compliance exist post employment contractual obligation include confidentiality agreement nonsolicitation andor noncompetition agreement sign employee employer severance payable later day general release claim irrevocable year employment employee eligibility severance shall govern term condition severance pay plan johnson johnson affiliate company effect time termination level executive committee member discretionary bonus remuneration provide award bonus longterm incentive form voluntary additional remuneration shall determine accordance employer corporate executive compensation plan program effect executive committee member subject term condition individual plan program eligibility criterion payment plan program determine employer sole discretion employer modify repeal plan program discretion time right obligation employee plan program shall govern term plan program amend time time individual bonus agreement employer employee award voluntary additional form remuneration shall subject continued existence employment relationship employer employee employment agreement effect time remuneration pay describe section employee deduce legal entitlement say plan program provide accordance term thereof repeat award voluntary additional remuneration scope say plan program shall rise entitlement future payment annual performance bonus base employee position group worldwide chair executive committee member employee annual bonus target opportunity annual base salary applicable deduction performance year payable quarter currently corporate executive plan effect executive employee level bonus pay cash share employer common stock term current plan share award annual performance bonus fully vest grant longterm incentive compensation base employee position employee current longterm incentive lti fair value target opportunity employee base salary performance year grant quarter award comprise combination stock option rsus performance share unit psus accordance employer executive compensation plan program awards vest year date grant compensation generally provide respect employee sign bonus section replacement rsus section start base salary performance year performance bonus lti compensation target grant compensation management sole discretion contingent employee individual performance performance employer performance criterion define employer compensation plan employee length service year grant guideline continue eligibility determine annually subject change year year continuation compensation program subject management discretion salary nonsalary compensation base guideline eligibility employee performance determine yearend employer result assess pay grant quarter follow year employment employee eligible salary bonus lti compensation commensurate employee similarly situate employee title report level responsibilite individual tax obligation arise base employee employment jurisdiction solely employee employer responsibility directly indirectly respect obligation include obligation pay reimburse gross payment employee benefit program employee eligible participate current executive benefit program current employee medical dental life accidental insurance coverage k plan pension plan commensurate employee position employee eligible participate employer medical benefit plan commence start date expense reimbursement travel expense shall subject pay basis relevant policy parent govern expense include johnson johnson global travel entertainment policy amend time time vacation employee entitle day pay vacation year employee total vacation float holiday entitlement base employee start date prorate accord current vacation holiday policy grant float holiday management sole discretion announce annually relocation employee relocation administer accordance term employer current relocation policy employee voluntarily terminate employment employment terminate cause define section month start date employee require reimbursethe employer affiliate relocation cost pay employee behalf employee understand agree require sign employer relocation repayment agreement return sign employment agreement employee understand employment atwill relocation repayment agreement contract employment imply employee employment continue period time confer right respect duration employment employee repayment obligation employment terminate cause resign good reason define section confidentiality noncompetition nonsolicitation condition enter employment agreement employee enter abide employee secrecy intellectual property noncompetition nonsolicitation agreement attach hereto effective start date employment application preemployment form employee understand agree satisfactorily complete follow prior start date background reference check employer confirm satisfied preplacement health evaluation include drug screen employment application employer background release form employer confirm complete work authorization paper documentation assignment employer sole discretion transfer assign employment agreement employee employment pursuant employment agreement affiliate employer case affiliate automatically employee employer employee consent require transaction long affiliate assume liability obligation duty employer contain employment agreement common ground program employer employ employee dispute resolution program common ground exclusive mean attempt quickly resolve dispute employee employer party agree program employment relate claim refer nonbinding mediation prior litigation information common ground program provide attach brochure miscellaneous employment agreement policy rule employer constitute entire agreement understanding party respect employment employee employer shall supersede prior oral write agreement understanding party relate hereto agree party write representation statement form employee connection employee employment incorporate employment agreement shall valid bind employer amendment employment agreement shall valid writing provision employment agreement find competent authority void invalid unenforceable provision shall deem delete employment agreement remain provision employment agreement shall continue force event employment agreement shall construe necessary amend way effect approximate achieve result close legally possible result intend provision hereof determined void illegal unenforceable employment agreement contrary notwithstanding intend amount payable employment agreement exempt comply section internal revenue code amend regulation guidance interpretive authority issue thereunder collectively section subject employee payment additional tax penalty interest impose section employment agreement interpret basis consistent intent b extent reimbursement expense provision inkind benefit employment agreement subject section expense eligible reimbursement inkind benefit provide calendar year shall affect expense eligible reimbursement inkind benefit provide calendar year provide clause violate regard expense reimburse arrangement cover code section b solely expense subject limit relate period arrangement effect ii reimbursement expense shall later december year follow calendar year expense incur iii employee right receive reimbursement inkind benefit shall subject liquidation exchange benefit c employee specify employee mean treasury regulation section date employee separation service mean treas reg section ah payment benefit pursuant employment agreement account employee separation service extent payment constitute nonqualifie defer compensation subject section require delay pursuant section aabi code take account exclusion applicable payment section shall business day expiration month date employee separation service ii early date employee death delay period expiration delay period payment benefit delay pursuant employment agreement payable single sum installment absence delay pay reimburse employee lump sum remain payment benefit employment agreement pay provide accordance normal payment date specify notwithstanding provision employment agreement contrary purpose provision employment agreement provide payment amount benefit follow termination employment consider deferred compensation section reference employee termination employment corollary term employer shall construe refer employee separation service mean treas reg section ah employer payment employment agreement installment installment shall deem separate payment purpose section payment employment agreement specify payment period reference number day eg payment thirty day follow date termination actual date payment specified period shall sole discretion employer e extent payable employee subject employee enter release claim employer deferral compensation section payable taxable year employee time payment subject term condition plan program agreement company satisfy section payment shall applicable january later date early day date release irrevocable later taxable year shall include payment date applicable law employment agreement subject new jersey law addendum agreement document attach employment agreement amend time time form integral employment agreement effective date agreement agreement effective late date precondition employee employment meet date party employee sign execute agreement effective offer employment agreement govern section employer johnson johnson peter fasolo peter fasolo date august worldwide vicepresident human resource employee sandra e peterson sandra e peterson sandra e peterson date august addendum policy business conduct employee secrecy intellectual property noncompetition nonsolicitation agreement relocation repayment agreement performance standard conduct policyexhibit johnson johnson subsidiaries statement computation ratio earning fix charge dollar million fiscal year end january january december december january determination earning earning provision taxis income fix charge capitalize interest total earning define fix charge estimate interest portion rent expense interest expense capitalization interest total fix charge ratio earning fix charge ratio earning fix charge compute divide sum earning provision taxis income fix charge fix charge fix charge represent interest expense interest capitalize amortization debt discount appropriate interest factor operate leasestable content management discussion analysis result operation financial condition organization business segment result operation analysis sale business segment analysis consolidate earning provision taxis income liquidity capital resource information cautionary factor affect future result audit consolidated financial statement consolidate balance sheet consolidate statement earning consolidate statement comprehensive income consolidate statement equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm management report internal control financial reporting support schedule summary operation statistical data shareholder return performance graph johnson johnson annual report management discussion analysis result operation financial condition organization business segment description company business segment johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device diagnostic consumer segment include broad range product baby care skin care oral care wound care women health field nutritional overthecounter pharmaceutical product wellness prevention platform product market general public sell retail outlet distributor world pharmaceutical segment include product follow area antiinfective antipsychotic contraceptive gastrointestinal hematology immunology infectious disease neurology oncology pain management thrombosis vaccine product distribute directly retailer wholesaler health care professional prescription use medical device diagnostic segment include broad range product distribute wholesaler hospital retailer principally professional field physician nurse hospital clinic include product treat cardiovascular disease orthopaedic neurological product blood glucose monitor insulin delivery product general surgery biosurgical energy product professional diagnostic product infection prevention product disposable contact lense company structure base principle decentralize management executive committee johnson johnson principal management group responsible strategic operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device diagnostic business segment product line company compete company locally globally world competition exist product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new innovative product important company success area business include protect company portfolio intellectual property competitive environment require substantial investment continue research maintain sale force addition development maintenance customer demand company consumer product involve significant expenditure advertising promotion management objective company manage strategic framework aim achieve sustainable growth accomplish company management operate business consistent certain strategic principle prove successful time end company participate growth area human health care commit attain leadership position growth area development high quality innovative product service new product introduce past year account approximately sale billion sale invest research development investment reflect management commitment importance ongoing development new differentiate product service sustain longterm growth operating company locate country company view principle decentralize management asset fundamental success broadly base business foster entrepreneurial spirit combine extensive resource large organization ability anticipate react quickly local market change challenge company commit develop global business leader achieve growth objective business manage longterm order sustain leadership position achieve growth provide endure source value shareholder credo unify management team company dedicated employee achieve objective provide common set value serve constant reminder company responsibility customer employee communitie shareholder company believe basic principle overall mission improve quality life people enable johnson johnson continue leader health care industry result operation analysis consolidate sale worldwide sale increase billion compare increase decrease sale change consist follow johnson johnson annual report sale increasedecrease volume price currency total sale company billion billion billion represent increase decrease sale international company billion billion billion represent increase acquisition synthes inc net relate divestiture increase total worldwide sale growth operational growth fiveyear compound annual growth rate worldwide international sale respectively tenyear compound annual growth rate worldwide international sale respectively sale europe experience decline compare prior year include operational growth offset negative currency impact sale western hemisphere exclude achieve growth compare prior year include operational growth negative currency impact sale asiapacific africa region achieve growth compare prior year include operational growth negative currency impact company customer represent total consolidated revenue health care reform provision patient protection affordable care act health care education reconciliation act begin company sell brand prescription drug specify government program pay annual nontax deductible fee base allocation company market share total brand prescription drug sale prior year fullyear impact sell marketing administrative expense approximately million million current law begin company require pay tax deductible excise tax impose sale certain medical device excise tax estimate million record cost product sell statement earning net trade sale impact health care reform legislation annual reduction approximately million million respectively increase sale rebate discount analysis sale business segment consumer segment consumer segment sale billion decrease include operational growth offset negative currency impact consumer segment sale billion decrease international sale billion decrease include operational growth offset negative currency impact major consumer franchise sale change dollar million vs vs otc pharmaceutical nutritional skin care baby care womens health oral care wound careother total consumer sale overthecounter otc pharmaceutical nutritional franchise sale billion decrease sale decrease primarily low sale analgesic result supply constraint competitive pressure nutritional product strong growth upper respiratory digestive health analgesic product outside offset negative currency mcneilppc inc continue operate consent decree sign food drug administration fda govern certain mcneil consumer healthcare manufacturing operation mcneil continue johnson johnson annual report operate manufacturing facility las piedras puerto rico lancaster pennsylvania production volume facility continue impact additional review approval process require consent decree company expect continue plant operate consent decree produce simplify portfolio focus key brand fort washington pennsylvania manufacturing site operation time mcneil continue work resite product previously produce fort washington facility facility skin care franchise sale billion decrease increase sale neutrogena productsin offset competition economic condition outside baby care franchise sale billion decrease decline sale impact negative currency partially offset increase sale haircare wipe outside womens health franchise sale billion decrease primarily impact divestiture certain brand oral care franchise sale flat compare prior year increase sale listerine product outside partially offset competitive pressure usthe wound careother franchise sale billion decrease divestiture competitive pressure negative currency impact franchise consumer segment sale billion increase operational decline offset positive currency impact consumer segment sale billion decrease international sale billion increase include operational growth positive currency impact johnson johnson annual report pharmaceutical segment pharmaceutical segment achieve sale billion represent increase prior year operational growth negative currency impact sale billion increase international sale billion increase include operational growth negative currency impact major pharmaceutical therapeutic area sale change dollar million vs vs total immunology remicade simponi stelara immunology total infectious disease intelence levaquinfloxin prezista infectious disease total neuroscience concertamethylphenidate invega invega sustennaxeplion risperdal consta neuroscience total oncology doxilcaelyx velcade zytiga oncology total aciphexpariet procriteprex total pharmaceutical sale prior year amount reclassify conform current year presentation percentage great immunology product achieve sale billion represent increase compare prior year increase sale simponi golimumab remicade infliximab primarily market growth impact agreement merck co inc merck effective july distribution right remicade simponi certain territory relinquish company merck additional contributor increase sale stelara ustekinumab infectious disease product achieve sale billion represent increase compare prior year major contributor incivo telaprevir continue momentum market share growth prezista darunavir edurant rilpivirine intelence etravirine partially offset low sale levaquin levofloxacinfloxin ofloxacin loss market exclusivity june neuroscience product sale billion decline compare prior year growth impact generic competition concertamethylphenidate razadyne galantamine risperdalrisperidone duragesicfentanyl transdermal fentanyl transdermal system decline company longacte injectable johnson johnson annual report antipsychotic risperdal constarisperidone offset strong sale invega sustennaxeplion paliperidone palmitate invega paliperidone palmitate company supply distribution agreement watson laboratories inc distribute authorize generic version concerta effective original concerta patent expire party receive approval fda manufacture market generic version concerta generic version concerta launch december result reduction concerta sale oncology product achieve sale billion represent increase compare prior year growth primarily sale zytigaabiraterone acetate velcade bortezomib growth partially offset low sale doxildoxorubicin hci liposome injectioncaelyxpegylate liposomal doxorubicin hydrochloride supply constraint company thirdparty manufacturer company work restore reliable supply doxilcaelyx access restore alternate manufacturing approach approve european union eu japan late canada january european union caelyx manage access program place ensure patient complete course treatment remain place supply caelyx restore february fda approve generic version doxil pharmaceutical sale billion decline compare prior year primarily divestiture low sale aciphexparietrabeprazole sodium eprex epoetin alfa primarily impact generic competition result partially offset sale growth xareltorivaroxaban company receive regulatory approval include approval new mg tablet prezista darunavir daily oral administration treatment human immunodeficiency virus hiv treatmentnaive treatmentexperience adult patient darunavir resistance associate mutation fda approval expand use xareltorivaroxaban treat deepvein thrombosis dvt pulmonary embolism pe reduce risk recurrent dvt pe follow initial treatment fda grant accelerated approval sirturo bedaquiline tablet treatment pulmonary multidrug resistant tuberculosis combination therapy adult fda approve supplemental new drug application nda nucynta er tapentadol extendedrelease tablet oral analgesic take twice daily management neuropathic pain associate diabetic peripheral neuropathy adult fda european commission approve expand indication zytiga abiraterone acetate combination prednisone allow use chemotherapy treatment metastatic castrationresistant prostate cancer addition european commission approve marketing authorization dacogen decitabine treatment adult patient age year newly diagnose de novo secondary acute myeloid leukemia candidate standard induction chemotherapy subcutaneous administration velcade bortezomib treatment multiple myeloma company submit new drug application include nda fda marketing authorization application maa european medicine agency ema seek approval use canagliflozin oral oncedaily selective sodium glucose cotransporter sglt inhibitor treatment adult patient type diabete nda seek approval fixeddose therapy combine canagliflozin immediate release metformin treat patient type diabete additional submission include supplemental biologic license application fda type ii variation ema request approval stelara ustekinumab treatment adult patient active psoriatic arthritis biologic license application fda request approval investigational intravenous formulation antitumor necrosis factor tnfalpha simponi golimumab treatment adult moderately severely active rheumatoid arthritis addition supplemental biologic license application submit fda type ii variation submit ema request approval simponi golimumab treatment moderately severely active ulcerative colitis adult patient inadequate response conventional therapy include corticosteroid mercaptopurine mp azathioprine aza intolerant medical contraindication therapy finally maa submit ema seek conditional approval use bedaquiline tmc oral treatment combination therapy pulmonary multidrug resistant tuberculosis adult pharmaceutical segment sale billion increase operational growth positive currency impact sale billion decrease international sale billion increase include operational growth positive currency impact medical device diagnostic segment medical device diagnostic segment achieve sale billion represent increase prior year operational growth negative currency impact sale billion increase compare prior year international sale billion increase prior year operational growth negative currency impact acquisition synthes inc net relate divestiture increase total sale growth operational growth medical device diagnostic segment johnson johnson annual report major medical device diagnostic franchise sale change dollar million vs vs orthopaedic surgical care vision care diabetes care specialty surgery diagnostic cardiovascular care infection preventionother total medical device diagnostic sale prior year amount reclassify conform current year presentation orthopaedic franchise achieve sale billion increase prior year growth primarily sale newly acquire product synthe inc sale joint reconstruction mitek sport medicine product sale impact divestiture surgical instrument business codman shurtleff inc fiscal fourth quarter divestiture certain right asset relate depuy trauma business positive impact orthopaedic franchise total sale growth operational growth newly acquire product synthes inc net relate trauma business divestiture surgical care franchise sale billion decrease prior year low sale mechanical breast care pelvic floor product partially offset increase sale suture endoscopy product success echelon flex power endopath stapler vision care franchise achieve sale billion increase prior year growth drive acuvue trueye day acuvue moist astigmatism day acuvue moist diabetes care franchise sale billion decrease versus prior year sale growth asia latin america offset negative impact currency specialty surgery franchise achieve sale billion increase prior year incremental sale acquisition sterilme inc sale biosurgery product international sale energy product major contributor growth diagnostic franchise sale billion decline versus prior year decline primarily low sale donor screen competitive pressure divestiture rhogam business quarter january company announce explore strategic alternative orthoclinical diagnostic business include possible divestiture cardiovascular care franchise sale billion decline versus prior year sale impact company decision exit drugelute stent market second quarter low sale endovascular product impact competitive launch disruption supply resolve late quarter decline sale partially offset strong growth biosense webster electrophysiology business primarily success thermocool catheter launch infection preventionother franchise achieve sale billion increase prior year primarily growth advanced sterilization business medical device diagnostic segment achieve sale billion represent increase prior year operational growth positive currency impact sale billion decrease compare prior year international sale billion increase prior year operational growth positive currency impact analysis consolidate earning provision taxis income consolidated earning provision taxis income increase billion billion compare billion increase earning provision taxis income favorable increase gross profit billion billion decrease sell marketing administrative expense cost containment initiative business low litigation expense billion low charge billion relate depuy asr hip program versus prior year partially offset billion charge attributable asset writedown impairment inprocess research development primarily related crucell vaccine business discontinuation phase iii clinical development bapineuzumab iv billion integration currency cost relate acquisition synthes inc versus prior year include billion restructuring charge net johnson johnson annual report inventory writeoff include cost product sell related cardiovascular care business additionally include high gain divestiture item billion record income expense net decrease compare primarily cost associate litigation include product liability impact otc depuy asr hip recall restructure expense relate cardiovascular care business additionally investment spending fee brand pharmaceutical product incur health care reform legislation integration cost include inventory stepup charge associate acquisition crucell contribute decrease earning partially offset gain divestiture percent sale consolidated earning provision taxis income versus cost product sell sell marketing administrative expense cost product sell sell marketing administrative expense percent sale follow sale cost product sell percent point increase prior year sell marketing administrative expense percent point decreaseincrease prior year cost product sell percent sale increase compare prior year primarily result amortization inventory stepup charge billion amortization intangible relate synthes inc acquisition billion ongoing remediation cost mcneil otc business decrease percent sale sell marketing administrative expense compare prior year primarily cost containment initiative business prior year period include high investment spend pharmaceutical business new product cost product sell percent sale increase compare prior year primarily attributable ongoing remediation cost mcneil otc business inventory writeoff restructure cardiovascular care business addition low margin integration cost include inventory stepup charge associate acquisition crucell negatively impact cost product sell percent sale sell marketing administrative expense increase compare prior year primarily investment spending fee brand pharmaceutical product incur health care reform legislation research development expense research development expense segment business follow dollar million sale sale sale consumer pharmaceutical medical device diagnostic total research development expense percent increasedecrease prior year percent segment sale research development activity represent significant company business expenditure relate process discover testing develop new product improve exist product ensure product efficacy regulatory compliance prior launch company remain committed invest research development aim deliver high quality innovative product worldwide cost research development activity increase compare decrease medical device diagnostic segment primarily discontinuation clinical development program nevo sirolimuselute coronary stent inprocess research development iprd company record charge billion include billion impairment iprd relate discontinuation phase iii clinical development bapineuzumab iv partial impairment iprd relate crucell vaccine business billion billion impairment iprd relate discontinuation phase iii clinical development bapineuzumab iv billion johnson johnson annual report attributable noncontrolle interest charge relate development project recently discontinue delayed income expense net income expense net include royalty income gain loss relate sale writedown certain investment equity security hold johnson johnson development corporation gain loss disposal property plant equipment currency gain loss litigation settlement favorable change billion income expense net primarily low expense billion relate litigation include product liability billion cost relate depuy asr hip program partially offset billion attribute asset writedown primarily relate crucell vaccine business billion high integrationtransaction currency cost relate acquisition synthes inc unfavorable change billion income expense net primarily net litigation include product liability billion compare billion net gain litigation additionally compare include high expense billion cost relate depuy asr hip program adjustment billion value currency option deal cost relate acquisition synthes inc include high gain divestiture business billion compare restructure cordis corporation subsidiary johnson johnson announce discontinuation clinical development program nevo sirolimuselute coronary stent cessation manufacture marketing cypher cypher select plus sirolimuselute coronary stent end company record pretax charge billion billion include cost product sell restructuring charge note consolidated financial statement additional detail relate restructure interest income expense interest income decrease million compare prior year low rate interest earn low average cash balance cash cash equivalent marketable security total billion end average billion compare billion average cash balance decline average cash balance acquisition synthes inc partially offset cash generate operating activity interest expense decrease million compare low average debt balance average debt balance billion versus billion total debt balance end billion compare billion end reduction debt approximately billion primarily reduction commercial paper interest income decrease million compare prior year low rate interest earn despite high average cash balance cash cash equivalent marketable security total billion end average billion compare billion average cash balance increase average cash balance primarily cash generate operating activity net cash proceed divestiture interest expense increase million compare high average debt balance total debt balance end billion compare billion end high average debt balance billion versus billion increase borrowing company increase borrowing capitalize favorable term capital market proceed borrowing general corporate purpose segment pretax profit pretax profit segment business follow percent segment sale dollar million consumer pharmaceutical medical device diagnostic total expense allocate segment earning provision taxis income note consolidated financial statement detail amount allocate segment include interest income expense noncontrolle interest general corporate income expense billion billion currency relate expense acquisition synthes inc include respectively johnson johnson annual report consumer segment consumer segment pretax profit percent sale versus pretax profit unfavorably impact billion attribute intangible asset writedown approximately billion unfavorable product mix remediation cost associate mcneilppc inc consent decree partially offset cost containment initiative realize sell marketing administrative expense addition include high gain divestiture consumer segment pretax profit decrease primary driver decline operating profit unfavorable product mix remediation cost associate recall certain otc product partially offset gain divestiture monistat pharmaceutical segment pharmaceutical segment pretax profit percent sale versus pretax profit unfavorably impact charge billion attribute writedown asset impairment inprocess research development asset relate crucell vaccine business discontinuation phase iii clinical development bapineuzumab iv partially offset low litigation expense billion versus prior year favorable operating expense billion additionally include gain divestiture bystolicnebivolol ip right pharmaceutical segment pretax profit decrease primary driver decrease pretax profit margin high litigation expense record impact health care reform fee low margin integration cost include inventory stepup charge associate crucell acquisition partially offset gain divestiture animal health business ortho dermatologics gain relate company early investment crucell low manufacturing cost medical device diagnostic segment medical device diagnostic segment pretax profit percent sale versus medical device diagnostic segment pretax profit favorably impact profit synthe sale low expense billion litigation include product liability depuy asr hip program billion research development primarily discontinuation clinical development program nevo sirolimuselute coronary stent partially offset increase integration cost amortization inventory stepup billion associate acquisition synthes inc billion attribute writedown intangible asset addition include high gain divestiture versus prior year divestiture therakos business rhogam additionally include billion restructuring charge relate discontinuation clinical development program nevo sirolimuselute coronary stent medical device diagnostic segment pretax profit decrease primary driver decline pretax profit margin medical device diagnostic segment litigation expense include product liability cost associate depuy asr hip program restructure expense cost incur relate acquisition synthes inc increase investment spending provision taxis income worldwide effective income tax rate increase effective tax rate compare low tax benefit impairment inprocess research development intangible asset low tax jurisdiction increase taxable income high tax jurisdiction relative low tax jurisdiction exclusion benefit research development rd tax credit cfc lookthrough provision fiscal year financial result rd tax credit cfc lookthrough provision enact law retroactive january entire benefit rd tax credit cfc lookthrough provision reflect fiscal year financial result tax rate increase compare certain expense fully tax deductible high state taxis partially offset increase taxable income low tax jurisdiction relative high tax jurisdiction noncontrolle interest charge billion impairment iprd relate discontinuation phase iii clinical development bapineuzumab iv record billion impairment billion attributable noncontrolle interest liquidity capital resource liquidity cash flow cash cash equivalent billion end compare billion end primary use cash contribute billion decrease versus prior year approximately billion net cash investing activity billion net cash financing activity partially offset billion cash generate operating activity cash flow operation billion result billion net earning billion noncash charge primarily relate depreciation amortization asset writedown primarily inprocess research development stockbase compensation noncontrolle interest defer tax provision reduce billion relate change asset liability net effect acquisition investing activity use billion primarily billion addition property plant equipment andacquisition net cash acquire billion partially offset net sale investment marketable securities johnson johnson annual report billion billion proceed disposal asset financing activity use billion repurchase common stock billion primarily acquisition synthe inc dividend shareholder billion net retirement short longterm debt billion partially offset billion net proceed stock option exercisedexcess tax benefit company continue access liquidity commercial paper market additional detail borrowing note consolidated financial statement company anticipate operate cash flow exist credit facility access commercial paper market provide sufficient resource fund operating need concentration credit risk global concentration credit risk respect trade account receivables continue limited large number customer globally adherence internal credit policy credit limit recent economic challenge italy spain greece portugal southern european region impact certain payment pattern historically long experience international market total net trade account receivable balance southern european region approximately billion december approximately billion january approximately billion december approximately billion january southern european region net trade account receivable balance relate company consumer vision care diabetes care business certain pharmaceutical medical device diagnostic customer line historical collection pattern remain balance net trade account receivable southern european region negatively impact time payment certain government own support health care customer certain distributor pharmaceutical medical device diagnostic local affiliate total net trade account receivable balance customer approximately billion december billion january company continue receive payment customer case late payment premium customer payment expect period time long year revenue trade receivable discount estimate period time collection allowance doubtful account increase customer immaterial date company continue work closely customer payment plan monitor economic situation appropriate action necessary financing market risk company use financial instrument manage impact foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract protect value certain foreign currency asset liability hedge future foreign currency transaction primarily relate product cost gain loss contract offset gain loss underlie transaction appreciation dollar december market rate increase unrealized value company forward contract million conversely depreciation dollar december market rate decrease unrealized value company forward contract million scenario gain loss forward contract offset gain loss underlie transaction impact future anticipate earning cash flow company hedge exposure fluctuation currency exchange rate effect certain asset liability foreign currency enter currency swap contract change spread foreign interest rate companys interest rate sensitive financial instrument increase decrease unrealized value company swap contract approximately million scenario maturity gain loss swap contract offset gain loss underlie transaction impact future anticipate cash flow company enter financial instrument trade speculative purpose company policy enter contract party equivalent credit rating counterpartie contract major financial institution significant concentration exposure counterparty management believe risk loss remote company access substantial source fund numerous bank worldwide september company secure new day credit facility total credit available company approximate billion expire september interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor plus applicable margin commitment fee agreement material total borrowing end billion billion respectively reduction debt approximately billion primarily reduction commercial paper net cash cash current marketable security net debt billion compare net cash billion total debt represent total capital shareholder equity total debt total capital shareholder equity share end compare yearend johnson johnson annual report increase summary borrowing find note consolidated financial statement contractual obligation commitment company contractual obligation primarily lease debt unfunded retirement plan significant obligation satisfy obligation company use cash operation follow table summarize company contractual obligation aggregate maturity december note consolidated financial statement detail longterm interest unfunded dollar million debt obligation debt obligation retirement plan operating lease total total tax matter note consolidated financial statement share repurchase dividend july company announce board director approve stock repurchase program authorize company buy billion company common stock january company repurchase aggregate million share johnson johnson common stock cost billion stock repurchase program complete company fund share repurchase program combination available cash debt pursuant accelerate stock repurchase agreement connection acquisition synthes inc company purchase common stock open market fiscal fourth quarter company increase dividend th consecutive year cash dividend pay share compare dividend share share dividend distribute follow quarter second quarter quarter fourth quarter total january board director declare regular quarterly cash dividend share payable march shareholders record february company expect continue practice pay regular cash dividend information critical accounting policy estimate management discussion analysis result operation financial condition base company consolidate financial statement prepare accordance accounting principle generally accept gaap preparation financial statement require management estimate assumption affect amount report revenue expense asset liability relate disclosure actual result differ estimate company believe understand certain key accounting policy estimate essential achieve insight company operating result financial condition key accounting policy include revenue recognition income taxis legal selfinsurance contingency valuation longlive asset assumption determine amount record pension employee benefit plan account stock johnson johnson annual report option revenue recognition company recognize revenue product sale good ship deliver title risk loss pass customer provision certain rebate sale incentive trade promotion coupon product return discount customer account reduction sale period relate sale record product discount grant base term arrangement direct indirect market participant market condition include price charge competitor rebate large medicaid rebate provision estimate base contractual term historical experience trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler thirdparty sellthrough market research datum internally generate information sale return generally estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall return reserve base historical return trend product market percent gross sale accordance company accounting policy company generally issue credit customer return good company sale return reserve account accordance gaap guidance revenue recognition right return exist sale return reserve record sale value sale return consumer pharmaceutical segment exclusively resalable sale return certain franchise medical device diagnostic segment typically resalable material company rarely exchange product inventory return product sale return reserve total company range annual net trade sale fiscal reporting year promotional program product list allowance cooperative advertising arrangement record year incur continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program base estimate sale volume incentive period record product sell company earn service revenue copromotion certain product year present service revenue total revenue include sale customer arrangement evaluate determine appropriate amount defer addition company enter collaboration arrangement contain multiple revenue generating activity amount collaborative partner arrangement recognize activity perform deliver base relative fair value upfront fee receive arrangement defer recognize performance period note consolidated financial statement additional disclosure collaboration reasonably likely change assumption calculate accrual rebate return promotion anticipate material effect financial statement company currently disclose impact change assumption quarterly annual filing material financial statement impact table progression accrue rebate return promotion reserve doubtful account reserve cash discount segment business fiscal year end december january johnson johnson annual report consumer segment balance balance dollar million begin period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million january record contra asset pharmaceutical segment balance balance dollar million begin period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million january record contra asset johnson johnson annual report medical device diagnostic segment balance balance dollar million begin period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million january record contra asset income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base current tax regulation rate change tax law rate affect record defer tax asset liability future company unrecognize tax benefit uncertain tax position company follow gaap prescribe recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return management believe change estimate material effect company result operation cash flow financial position december january cumulative amount undistribute international earning approximately billion billion respectively december january company foreign subsidiary hold balance cash cash equivalent amount billion billion respectively company provide defer taxis undistribute earning certain international subsidiary earning consider permanently reinveste company intend continue reinvest earning international operation company decide later date repatriate earning company require provide net tax effect amount company determine defer tax liability associate undistributed earning determination practical note consolidated financial statement information income taxis legal self insurance contingency company record accrual contingency include legal proceeding product liability claim arise normal course business accrual base management judgment probability loss applicable actuarially determined estimate company self insurance whollyowne captive insurance company insure certain limit addition accrual self insurance program claim exceed insurance coverage accrue loss probable amount reasonably estimate additionally company record insurance receivable amount thirdparty insurer recovery probable appropriate reserve receivables record estimate amount collect thirdparty insurer company follow provision gaap recording litigation relate contingency liability record loss probable reasonably estimate good estimate loss range accrue estimate range well minimum accrue johnson johnson annual report longlive intangible asset company assess change economic condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset assumption estimate change time necessary company record impairment charge employee benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide plan base assumption discount rate expect return plan asset expect salary increase health care cost trend rate note consolidated financial statement detail rate effect rate change companys result operation stock base compensation company recognize compensation expense associate issuance equity instrument employee services fair value award estimate date grant blackschole option valuation model expense financial statement vest period input assumption determine fair value expect life expect volatility riskfree rate dividend yield note consolidated financial statement additional information new accounting pronouncement refer note consolidated financial statement recently adopt accounting pronouncement recently issue accounting pronouncement adopt december economic market factor company aware product environment decade policymaker consumer business express concern rise cost health care response concern company longstande policy pricing product responsibly period united states weight average compound annual growth rate company net price increase health care product prescription overthecounter drug hospital professional product consumer price index cpi inflation rate continue effect worldwide economy consequently way company operate company account operation venezuela highly inflationary prior threeyear cumulative inflation rate surpass face increase cost company strive maintain profit margin cost reduction program productivity improvement periodic price increase february venezuelan government announce devaluation currency effect devaluation expect material impact company year result company expose fluctuation currency exchange rate change value dollar compare foreign currency company sale income expense increase decrease translation foreign sale approximately million income million company face worldwide health care change continue result pricing pressure include health care cost containment government legislation relate sale promotion reimbursement health care product change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage result current global economic downturn continue impact company business company operate environment increasingly hostile intellectual property right generic drug firm file abbreviate new drug application anda seek market generic form company key pharmaceutical product prior expiration applicable patent cover product event company successful defend patent claim challenge anda filing generic firm introduce generic version product issue result potential substantial market share revenue loss product information discussion litigation filer abbreviate new drug application note consolidated financial statement legal proceeding johnson johnson certain subsidiary involve lawsuit claim product liability intellectual property commercial matter governmental investigation legal proceeding arise time time ordinary course business company record accrual contingency probable liability incur loss reasonably estimate company accrue certain litigation matter continue monitor related legal issue adjust accrual new information development accordance accounting standard codification asc litigation regulatory matter currently disclose loss probable reasonably possible company unable determine estimate possible loss range loss amount accrue matter affect factor include damage seek johnson johnson annual report proceeding unsubstantiate indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute numerous party involve company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution report period matter aggregate material adverse effect company result operation cash flow period note consolidated financial statement information legal proceeding common stock market price company common stock list new york stock exchange symbol jnj february record holders common stock company composite market price range johnson johnson common stock high low high low quarter second quarter quarter fourth quarter yearend close johnson johnson annual report cautionary factor affect future result annual report contain forwardlooke statement forwardlooke statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement company undertake update forwardlooke statement result new information future event development risk uncertainty include limited general industry condition competition economic factor interest rate currency exchange rate fluctuation technological advance new product patent attain competitor challenge inherent new product development include obtain regulatory approval challenge patent significant litigation government action adverse company impact business combination financial distress bankruptcy experience significant customer supplier change governmental law regulation foreign health care reform trend health care cost containment increase scrutiny health care industry government agency change behavior spend pattern purchaser health care product service financial instability international economy sovereign risk disruption natural disaster manufacture difficulty delay complex global supply chain increase regulatory requirement product efficacy safety concern result product recall regulatory action company report year end december include exhibit discussion additional factor cause actual result differ expectation company note factor permit private security litigation reform act johnson johnson annual report johnson johnson subsidiaries consolidate balance sheet december january dollar million share share amount note asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note defer taxis income note prepay expense receivables total current asset property plant equipment net note intangible asset net note goodwill note defer taxis income note asset total asset liability shareholder equity current liability loan note payable note account payable accrue liability accrue rebate return promotions accrue compensation employee relate obligation accrue taxis income total current liability longterm debt note defer taxis income note employee relate obligation note liability total liability shareholder equity prefer stock par value authorize unissued share common stock par value share note authorize share issue share accumulate comprehensive income note retain earning common stock hold treasury cost note share share total shareholder equity total liability shareholder equity note consolidated financial statement johnson johnson annual report johnson johnson subsidiaries consolidate statement earning dollar share million share amount note sale customer cost product sell gross profit selling marketing administrative expense research development expense inprocess research development note interest income interest expense net portion capitalize note income expense net restructure note earning provision taxis income provision taxis income note net earning add net loss attributable noncontrolle interest net earning attributable johnson johnson net earning share attributable johnson johnson note basic dilute cash dividend share average share outstanding note basic diluted note consolidated financial statement johnson johnson annual report johnson johnson subsidiaries consolidate statement comprehensive income dollar million note net earning comprehensive income loss net tax foreign currency translation security unrealize hold gain loss arise period reclassification earning net change employee benefit plan prior service cost amortization period prior service cost current year gain loss amortization period gain loss current year effect exchange rate net change derivative hedge unrealize gain loss arise period reclassification earning net change comprehensive income loss comprehensive income comprehensive loss attributable noncontrolle interest net tax comprehensive income attributable johnson johnson tax effect comprehensive income fiscal year end respectively security million million million employee benefit plan million million million derivative hedge million million million foreign currency translation adjust income taxis relate permanent investment international subsidiary note consolidated financial statement johnson johnson annual report johnson johnson subsidiaries consolidate statement equity dollar million note accumulate treasury retain comprehensive common stock stock total earning income issue balance january net earning attributable johnson johnson cash dividend pay employee compensation stock option plan repurchase common stock comprehensive income net tax balance january net earning attributable johnson johnson cash dividend pay employee compensation stock option plan repurchase common stock comprehensive income net tax balance january net earning attributable johnson johnson cash dividend pay employee compensation stock option plan issuance common stock associate acquisition synthes inc repurchase common stock comprehensive income net tax balance december include repurchase common stock associate acquisition synthes inc note consolidated financial statement johnson johnson annual report johnson johnson subsidiaries consolidate statement cash flow dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow operating activity depreciation amortization property intangible stock base compensation noncontrolle interest asset writedown impairment defer tax provision account receivable allowance change asset liability net effect acquisition increase account receivable increase inventory increase account payable accrue liability increase current noncurrent asset decreaseincrease current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal asset acquisition net cash acquire note purchase investment sale investment primarily intangible net cash investing activity cash flow financing activity dividend shareholder repurchase common stock proceed shortterm debt retirement shortterm debt proceed longterm debt retirement longterm debt proceed exercise stock optionsexcess tax benefit net cash financing activity effect exchange rate change cash cash equivalent decreaseincrease cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flow datum cash pay year interest income taxis supplemental schedule noncash investing financing activity issuance common stock associate acquisition synthes inc treasury stock issue employee compensation stock option plan net cash proceed conversion debt johnson johnson annual report acquisition fair value asset acquire fair value liability assume noncontrolle interest net fair value acquisition issuance common stock associate acquisition synthes inc net cash pay acquisition note consolidated financial statement johnson johnson annual report note consolidated financial statement summary significant accounting policy principle consolidation consolidated financial statement include account johnson johnson subsidiaries company intercompany account transaction eliminate description company business segment company approximately employee worldwide engage research development manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device diagnostic consumer segment include broad range product baby care skin care oral care wound care women health field nutritional overthecounter pharmaceutical product wellness prevention platform product market general public sell retail outlet distributor world pharmaceutical segment include product follow area antiinfective antipsychotic contraceptive gastrointestinal hematology immunology infectious disease neurology oncology pain management thrombosis vaccine product distribute directly retailer wholesaler health care professional prescription use medical device diagnostic segment include broad range product distribute wholesaler hospital retailer principally professional field physician nurse hospital clinic include product treat cardiovascular disease orthopaedic neurological product blood glucose monitor insulin delivery product general surgery biosurgical energy product professional diagnostic product infection prevention product disposable contact lense new accounting pronouncement recently adopt accounting pronouncement fiscal quarter company adopt financial accounting standard board fasb guidance amendment issue related goodwill impairment testing amendment update entity option assess qualitative factor determine existence event circumstance lead determination likely fair value report unit carrying assess totality event circumstance entity determine likely fair value report unit carrying perform twostep impairment test unnecessary entity conclude require perform step twostep impairment test update effective annual interim goodwill impairment test perform fiscal year begin december adoption standard material impact company result operation cash flow financial position fiscal quarter company adopt fasb amendment disclosure requirement presentation comprehensive income amendment require nonowner change stockholder equity present single continuous statement comprehensive income separate consecutive statement guidance effective retrospectively interim period annual period begin december fiscal quarter company adopt fasb amendment disclosure requirement fair value measurement amendment result convergence fair value measurement disclosure requirement generally accept accounting principle gaap international financial reporting standard ifrs guidance effective prospectively interim period annual period begin december adoption standard material impact company result operation cash flow financial position recently issue accounting standard adopt december fiscal quarter fasb issue guidance amendment relate testing indefinite live intangible asset impairment amendment update entity option assess qualitative factor determine existence event circumstance indicate likely indefinitelive intangible asset impair assess totality event circumstance entity conclude likely indefinitelive intangible asset impair entity require determine fair value entity conclude require determine fair value indefinitelive intangible asset perform quantitative impairment test entity option bypass qualitative assessment indefinitelive intangible asset period proceed directly perform quantitative impairment test update effective annual interim impairment test perform fiscal year begin september johnson johnson annual report early adoption permit adoption standard expect material impact company result operation cash flow financial position february fasb issue guidance relate additional reporting disclosure amount reclassify accumulated comprehensive income oci new guidance company require disclose income loss reclassify oci respective line item income statement net income present guidance allow company elect disclose reclassification note financial statement face income statement update effective annual interim reporting period fiscal year begin december adoption standard expect material impact company result operation cash flow financial position cash equivalent company consider security maturity month purchase cash equivalent investment shortterm marketable security carry cost approximate fair value investment classified availableforsale carry estimate fair value unrealize gain loss record component accumulate comprehensive income longterm debt security company ability intent hold maturity carry amortize cost management determine appropriate classification investment debt equity security time purchase reevaluate determination balance sheet date company periodically review investment equity security impairment adjust investment fair value decline market value deem temporary loss security consider temporary loss recognize earning property plant equipment depreciation property plant equipment state cost company utilize straightline method depreciation estimate useful life asset building building equipment year land leasehold improvement year machinery equipment year company capitalize certain computer software development cost include machinery equipment incur connection develop obtain computer software internal use capitalize software cost amortize estimate useful life software generally range year company review longlive asset assess recoverability undiscounted cash flow certain event change operate economic condition occur impairment assessment perform recoverability carrying value asset asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow revenue recognition company recognize revenue product sale good ship deliver title risk loss pass customer provision certain rebate sale incentive trade promotion coupon product return discount customer account reduction sale period relate sale record product discount grant base term arrangement direct indirect market participant market condition include price charge competitor rebate large medicaid rebate provision estimate base contractual term historical experience trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler thirdparty sellthrough market research datum internally generate information sale return generally estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall return reserve base historical return trend product market percent gross sale accordance company accounting policy company generally issue credit customer return good company sale return reserve account accordance gaap guidance revenue recognition right return exist sale return reserve record sale value sale return consumer pharmaceutical segment exclusively resalable sale return certain franchise medical device diagnostic segment typically resalable material company rarely exchange product inventory johnson johnson annual report return product sale return reserve total company range annual sale customer fiscal reporting year promotional program product list allowance cooperative advertising arrangement record year incur continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program base estimate sale volume incentive period record product sell company earn service revenue copromotion certain product include sale customer arrangement evaluate determine appropriate amount defer shipping handle shipping handling cost incur million million million respectively include sell marketing administrative expense revenue receive shipping handle sale customer period present inventory inventory state low cost market determine firstin firstout method intangible asset goodwill authoritative literature gaap require goodwill intangible asset indefinite life assess annually impairment company complete annual impairment test fiscal fourth quarter future impairment test perform annually fiscal fourth quarter soon warrant case certain indefinite live intangible asset fiscal second quarter purchase inprocess research development account indefinite live intangible asset underlie project complete point intangible asset account definite live intangible asset abandon point intangible asset write partially impair intangible asset finite useful life continue amortize useful life review impairment warrant economic condition note detail intangible asset goodwill financial instrument require gaap derivative instrument record balance sheet fair value fair value exit price receive sell asset pay transfer liability fair value marketbase measurement determine assumption market participant use price asset liability authoritative literature establish threelevel hierarchy prioritize input measure fair value level high priority level low change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction company document relationship hedge item derivative overall risk management strategy include reason undertake hedge transaction enter derivative objective strategy minimize foreign currency exposure impact company financial performance protect company cash flow adverse movement foreign exchange rate ensure appropriateness financial instrument manage enterprise risk associate financial institution note additional information financial instrument product liability accrual product liability claim record undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically additional information available result cost availability factor effective november company cease purchase thirdparty product liability insurance company self insurance whollyowne captive insurance company insure certain limit addition accrual self insurance program claim exceed insurance coverage accrue loss probable amount reasonably estimate base availability prior coverage receivables insurance recovery relate product liability claim record undiscounted basis probable recovery realize appropriate reserve receivables record estimate amount collect thirdparty insurer concentration credit risk global concentration credit risk respect trade account receivables continue limited large number customer globally adherence internal credit policy credit limit recent economic challenge italy spain greece portugal southern european region impact certain payment pattern historically long experience international market total net trade account receivable balance johnson johnson annual report southern european region approximately billion december approximately billion january approximately billion december approximately billion january southern european region net trade account receivable balance relate company consumer vision care diabetes care business certain pharmaceutical medical device diagnostic customer line historical collection pattern remain balance net trade account receivable southern european region negatively impact time payment certain government own support health care customer certain distributor pharmaceutical medical device diagnostic local affiliate total net trade account receivable balance customer approximately billion december billion january company continue receive payment customer case late payment premium customer payment expect period time long year revenue trade receivable discount estimate period time collection allowance doubtful account increase customer immaterial date company continue work closely customer payment plan monitor economic situation appropriate action necessary research development research development expense expense incurred upfront milestone payment party connection research development collaboration expense incur point regulatory approval payment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize payment include intangible net accumulate amortization company enter collaborative arrangement typically pharmaceutical biotechnology company develop commercialize drug candidate intellectual property arrangement typically involve party active participant collaboration expose significant risk reward dependent commercial success activity collaboration usually involve activity party include research development marketing selling distribution collaboration require upfront milestone royalty profit share payment contingent occurrence certain future event link success asset development amount collaborative partner relate development activity generally reflect reduction research development expense performance contract development service central company operation general income statement presentation collaboration follow naturetype collaboration statement earning presentation thirdparty sale product sale customer royaltiesmilestone pay collaborative partner postregulatory approval cost good sell royalty receive collaborative partner income expense net upfront payment milestone pay collaborative partner preregulatory research development expense approval research development payment collaborative partner research development expense research development payment receive collaborative partner reduction research development expense milestone capitalize intangible asset amortize cost good sell useful life year present individual project represent great total annual consolidated research development expense advertising cost associate advertising expense year incur include sell marketing administrative expense advertising expense worldwide comprise television radio print medium internet advertising billion billion billion respectively income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base current tax regulation rate change tax law rate affect record defer tax asset liability future johnson johnson annual report company unrecognize tax benefit uncertain tax position company follow gaap prescribe recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return management believe change estimate material effect company result operation cash flow financial position december january cumulative amount undistribute international earning approximately billion billion respectively december january company foreign subsidiary hold balance cash cash equivalent amount billion billion respectively company provide defer taxis undistribute earning certain international subsidiary earning consider permanently reinveste company intend continue reinvest earning international operation company decide later date repatriate earning company require provide net tax effect amount company determine defer tax liability associate undistributed earning determination practicable note consolidated financial statement information income taxis net earning share basic earning share compute divide net earning available common shareholder weight average number common share outstanding period dilute earning share reflect potential dilution occur security exercise convert common stock treasury stock method use estimate preparation consolidate financial statement conformity accounting principle generally accept require management estimate assumption affect amount report estimate accounting sale discount rebate allowance incentive product liability income taxis depreciation amortization employee benefit contingency intangible asset liability valuation actual result differ estimate company follow provision gaap recording litigation relate contingency liability record loss probable reasonably estimate good estimate loss range accrue estimate range well minimum accrue annual closing date company follow concept fiscal year end sunday nearest end month december normally fiscal year consist week year fiscal year consist week case case reclassification certain prior period amount reclassify conform current year presentation cash cash equivalent current marketable security end cash cash equivalent current marketable security comprise dollar million cash government security obligation corporate debt security money market fund time deposit total cash cash equivalent current marketable security estimate fair value amortize cost december estimate fair value million january reflect million unrealized gain government security obligation december current marketable security consist million million government security obligation corporate debt security respectively january current marketable security consist million million government security obligation corporate debt security respectively fair value government security obligation corporate debt security estimate quote broker price significant observable input company invest excess cash deposit major bank world highquality money market instrument company policy make investment commercial institution johnson johnson annual report equivalent credit rating inventory end inventory comprise dollar million raw material supply good process finish good total inventory december remain inventory stepup relate synthes inc acquisition approximately million property plant equipment end property plant equipment cost accumulate depreciation dollar million land land improvement building build equipment machinery equipment construction progress total property plant equipment gross accumulate depreciation total property plant equipment net company capitalize interest expense cost construction facility equipment interest expense capitalize million million million respectively depreciation expense include amortization capitalize interest billion billion billion respectively retirement disposal property plant equipment cost relate amount accumulate depreciation amortization eliminate asset accumulate depreciation account respectively difference net asset value proceed record earning intangible asset goodwill end gross net amount intangible asset dollar million intangible asset definite life patent trademark gross accumulate amortization patent trademark net customer relationship intangible gross accumulate amortization customer relationship intangible net intangible asset indefinite live trademark purchase inprocess research development total intangible asset indefinite live total intangible asset net goodwill december january allocate segment business follow johnson johnson annual report med device dollar million consumer pharmaceutical diagnostic total goodwill january acquisition currency translationother goodwill january acquisition currency translationother goodwill december weight average amortization period patent trademark customer relationship intangible asset year year respectively amortization expense amortizable asset million million million tax fiscal year end december january january respectively estimate amortization expense succeed year approximate million tax year amortization expense include cost product sell intangible asset goodwill increase billion billion respectively base purchase price allocation synthes inc acquisition note consolidated financial statement additional detail synthes inc acquisition increase intangible asset partially offset billion intangible asset writedown billion impairment purchase inprocess research development primarily relate discontinuation phase iii clinical development bapineuzumab iv partial impairment relate crucell vaccine business fair value measurement company use forward exchange contract manage exposure variability cash flow primarily relate foreign exchange rate change future intercompany product thirdparty purchase raw material denominate foreign currency company use cross currency interest rate swap manage currency risk primarily relate borrowing type derivative designate cash flow hedge company use forward exchange contract manage exposure variability cash flow repatriation foreign dividend contract designate net investment hedge additionally company use forward exchange contract offset exposure certain foreign currency asset liabilitie forward exchange contract designate hedge change fair value derivative recognize earning offset current earning effect relate foreign currency asset liability company enter derivative financial instrument trade speculative purpose contain credit risk relate contingent feature requirement post collateral ongoing basis company monitor counterparty credit rating company consider credit nonperformance risk low company enter agreement commercial institution equivalent credit rating december company notional amount outstanding forward foreign exchange contract cross currency interest rate swap billion billion respectively derivative instrument record balance sheet fair value change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction designation cash flow hedge entrance date derivative contract inception derivative expect highly effective change fair value derivative designate cash flow hedge highly effective record accumulate comprehensive income underlie transaction affect earning reclassify earning account hedge transaction gainslosse net investment hedge account currency translation account insignificant ongoing basis company assess derivative continue highly effective offset change cash flow hedge item derivative long expect highly effective hedge accounting discontinue hedge ineffectiveness include current period earning income expense net december balance defer net gain derivative include accumulate comprehensive income million aftertax additional information consolidated statement comprehensive income note company expect substantially relate foreign exchange contract reclassify earning month result transaction expect occur period maximum length time company hedge transaction exposure month exclude interest rate swap ultimately realize earning differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity derivative follow table summary activity relate designate derivative fiscal year end december johnson johnson annual report january gainloss gainloss reclassify gainloss recognize dollar million recognize accumulate oci accumulate oci income incomeexpense cash flow hedge income statement caption sale customer cost product sell research development expense interest incomeinterest expense net income expense net total amount show table net tax effective portion ineffective portion foreign exchange contract cross currency interest rate swap fiscal year end december january gain million loss million respectively recognize income expense net relate foreign exchange contract designate hedge instrument fair value exit price receive sell asset pay transfer liability fair value marketbase measurement determine assumption market participant use price asset liability authoritative literature establish threelevel hierarchy prioritize input measure fair value level hierarchy describe level high priority level low fair value derivative financial instrument ie forward exchange contract currency swap aggregation currency future cash flow discount present value prevail market interest rate subsequently convert dollar current spot foreign exchange rate company believe fair value derivative instrument materially differ amount realize settlement maturity change fair value material effect company result operation cash flow financial position company hold equity investment classify level trade active exchange market company significant financial asset liability require revised valuation standard recognize fair value follow level input measure fair value level quote price active market identical asset liability level significant observable input level significant unobservable input johnson johnson annual report company significant financial asset liability measure fair value december january follow dollar million level level level total total derivative designate hedge instrument asset foreign exchange contract cross currency interest rate swap total liability foreign exchange contract cross currency interest rate swap total derivative designate hedge instrument asset foreign exchange contract swiss franc option total liability foreign exchange contract investment asset liability classify level exception investment million classify level include million million noncurrent asset fiscal year end december january respectively include million million noncurrent liability fiscal year end december january respectively cross currency interest rate swap relate outstanding eur gbp note mature november swap settle fair market value replace new swap currency option relate acquisition synthes inc expire january classify noncurrent asset note financial asset liability hold carrying consolidate balance sheet johnson johnson annual report borrowing component longterm debt follow dollar million effective rate effective rate debenture note debenture month libor frn month libor frn note note debenture debenture note b euro b euro zero coupon convertible subordinated debenture debenture note debenture note mm gbp mm gbp note debenture note debenture debenture note current portion weight average effective rate translation rate december translation rate january excess fair value carry value debt billion billion fair value noncurrent debt estimate market price corroborate quote broker price significant observable input company access substantial source fund numerous bank worldwide september company secure new day credit facility total credit available company approximate billion expire september interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor plus applicable margin commitment fee agreement material company continue access liquidity commercial paper market shortterm borrowing current portion longterm debt amount approximately billion end billion borrow commercial paper program remainder principally represent local borrowing international subsidiary company shelf registration securities exchange commission enable company issue debt security warrant purchase debt security timely basis johnson johnson annual report aggregate maturity longterm obligation commence dollar million income taxis provision taxis income consist dollar million currently payable tax international taxis total currently payable defer taxis international taxis total defer provision taxis income comparison income tax expense statutory rate company effective tax rate follow dollar million international earning taxis income tax rate statutory rate international operation exclude ireland ireland puerto rico operation research orphan drug tax credit state local manufacturing deduction tax international income effective tax rate include expense fully tax deductible primarily relate litigation expense increase effective tax rate compare low tax benefit impairment inprocess research development intangible asset low tax jurisdiction increase taxable income high tax jurisdiction relative low tax jurisdiction exclusion benefit research development rd tax credit cfc lookthrough provision fiscal year financial result rd tax credit cfc lookthrough provision enact law retroactive january entire benefit rd tax credit cfc lookthrough provision reflect fiscal year financial result increase tax rate compare primarily certain expense fully tax deductible high state taxis partially offset increase taxable income low tax jurisdiction relative high tax jurisdiction johnson johnson annual report temporary difference carryforward follow defer tax defer tax dollar million asset liability asset liability employee relate obligation stock base compensation depreciation nondeductible intangible international rd capitalize tax reserve liabilitie income report tax purpose net operating loss carryforward international miscellaneous international miscellaneous total deferred income taxis difference net defer tax income balance sheet net defer tax include taxis income balance sheet company whollyowne international subsidiary cumulative net loss company believe likely subsidiary realize future taxable income sufficient utilize defer tax asset follow table summarize activity relate unrecognized tax benefit dollar million begin year increase relate current year tax position increase relate prior period tax position decreases relate prior period tax position settlement lapse statute limitation end year unrecognize tax benefit billion december recognize affect company annual effective tax rate company conduct business file tax return numerous country currently tax audits progress number tax authority internal revenue service irs complete audit tax year limited number issue remain open prior tax year go major jurisdiction company conduct business year remain open generally year company believe possible audits complete tax authority jurisdiction month company able provide reasonably reliable estimate time future tax payment relate uncertain tax position company classifie liability unrecognize tax benefit relate interest penalty longterm liabilitie interest expense penalty relate unrecognized tax benefit classify income tax expense company recognize tax interest million expense million expense million income respectively total accrue interest million million respectively johnson johnson annual report employee relate obligation end employee relate obligation record consolidated balance sheet dollar million pension benefit postretirement benefit postemployment benefit defer compensation total employee obligation current benefit payable employee relate obligation noncurrent prepay employee relate obligation million million respectively include asset consolidate balance sheet pension benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide company provide postretirement benefit primarily health care eligible retire employee dependent international employee cover governmentsponsored program cost company significant retirement plan benefit primarily base employee compensation year retirement number year service international subsidiary plan fund deposit trustee annuity purchase group contract reserve provide company fund retiree health care benefit advance right modify plan future company use date consolidated financial statement december january respectively measurement date international retirement benefit plan net periodic benefit cost company define benefit retirement plan benefit plan include follow component retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost credit amortization net transition obligation recognize actuarial loss curtailment settlement net periodic benefit cost amount expect recognize net periodic benefit cost come year company define benefit retirement plan postretirement plan dollar million amortization net transition obligation amortization net actuarial loss amortization prior service cost unrecognized gain loss pension plan amortize average remain future service plan plan active employee amortize average life expectancy amortization gain johnson johnson annual report losse benefit plan determine corridor great market value asset project benefit obligation total unamortized gain loss excess corridor amortize average remain future service prior service costsbenefit pension plan amortize remain future service plan participant time plan amendment prior service costbenefit benefit plan amortize average remain service eligibility age plan participant time plan amendment weightedaverage assumption follow table represent rate develop actuarial present value project benefit obligation year list net periodic benefit cost follow year retirement plan benefit plan worldwide benefit plan discount rate expect longterm rate return plan asset rate increase compensation level company discount rate determine consider current yield curve represent high quality longterm fix income instrument result discount rate consistent duration plan liability expect rate return plan asset assumption represent company assessment longterm return diversify investment portfolio globally assessment determine projection external financial source longterm historical average actual return asset class asset class allocation market follow table display assume health care cost trend rate individual health care plan health care cost trend rate assume year rate cost trend rate assume decline ultimate trend year rate reach ultimate trend rate onepercentagepoint change assume health care cost trend rate follow effect onepercentage onepercentage dollar million point increase point decrease health care plan total interest service cost postretirement benefit obligation johnson johnson annual report follow table set forth information relate benefit obligation fair value plan asset yearend company define benefit retirement plan postretirement plan retirement plan benefit plan dollar million change benefit obligation project benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial loss divestiture acquisition curtailment settlement restructure benefit pay plan effect exchange rate project benefit obligation end year change plan asset plan asset fair value begin year actual return loss plan asset company contribution plan participant contribution settlement divestiture acquisition benefit pay plan asset effect exchange rate plan asset fair value end year fund status end year amount recognize company balance sheet consist follow noncurrent asset current liability noncurrent liability total recognize consolidated balance sheet end year amount recognize accumulate comprehensive income consist follow net actuarial loss prior service cost credit unrecognized net transition obligation total tax effect accumulate benefit obligation end year johnson johnson annual report retirement plan benefit plan dollar million change plan asset benefit obligation recognize comprehensive income net periodic benefit cost net actuarial loss amortization net actuarial loss gain prior service cost amortization prior service cost credit effect exchange rate total recognize comprehensive income tax total recognize net periodic benefit cost comprehensive income company plan continue fund qualified plan comply pension protection act international plan fund accordance local regulation additional discretionary contribution deem appropriate meet longterm obligation plan certain plan fund common practice funding provide economic benefit consequently company pension plan fund company contribute million million international pension plan respectively follow table display fund status company qualified nonqualified pension plan international fund unfunded pension plan december january respectively plan international plan qualified plan nonqualifie plan fund plan unfunded plan dollar million plan asset project benefit obligation accumulate benefit obligation fund status project benefit obligation accumulate benefit obligation plan accumulate benefit obligation excess plan asset accumulate benefit obligation project benefit obligation plan asset billion billion billion respectively end billion billion billion respectively end follow table display project future benefit payment companys retirement benefit plan dollar million project future benefit payment retirement plan benefit plan gross medicare rebate benefit plan net follow table display project future minimum contribution company international unfunded retirement plan amount include discretionary contribution company elect future johnson johnson annual report dollar million project future contribution unfunde retirement plan unfunde international retirement plan pension plan oversee local committee board responsible overall administration investment pension plan determine investment policy strategy goal committee board consider factor include local pension rule regulation local tax regulation availability investment vehicle separate account commingle account insurance fund etc funded status plan ratio active retiree duration liability relevant factor include diversification liquidity local market liquidity base currency majority company pension fund open new entrant expect ongoing plan permit investment primarily liquid andor list little reliance illiquid nontraditional investment hedge fund companys retirement plan asset allocation end target allocation follow percent target plan asset allocation worldwide retirement plan equity security debt security total plan asset determination fair value plan asset plan establish welldocumented process determine fair value fair value base quote market price available list price quote available fair value base model primarily use input marketbase independently source market parameter include yield curve interest rate volatilitie equity debt price foreign exchange rate credit curve plan believe valuation method appropriate consistent market participant use different methodology assumption determine fair value certain financial instrument result different estimate fair value report date valuation hierarchy authoritative literature establish threelevel hierarchy prioritize input measure fair value level hierarchy describe table level high priority level low financial instrument categorization valuation hierarchy base low level input significant fair value measurement follow description valuation methodology investment measure fair value shortterm investment cash quote shortterm instrument value closing price hold deposit custodian bank investment investment vehicle value net asset value nav provide administrator fund nav base value underlie asset own fund minus liability divide number share outstanding nav quote price market active classify level government agency security limit number investment value closing price report major market individual security trade quote price available active market investment classify level valuation hierarchy quote market price available specific security fair value estimate pricing model quote price security similar characteristic discount cash flow quote market price security available active market classify level debt instrument limit number investment value closing price report major market individual security trade quote price available active market investment classify level quote market price available specific security fair value estimate pricing model quote price security similar characteristic discount cash flow classify level level debt instrument price base unobservable input johnson johnson annual report equity security common stock value closing price report major market individual security trade substantially common stock classify level valuation hierarchy commingle fund investment public investment vehicle value nav provide fund administrator nav base value underlie asset own fund minus liability divide number share outstanding asset level category quote market price market active insurance contract instrument issue insurance company fair value base negotiate value underlie investment hold separate account portfolio consider credit worthiness issuer underlie investment government assetbacke fix income security general insurance contract classify level quote price observable input pricing asset asset represent primarily limit partnership real estate investment commercial loan commercial mortgage classify corporate debt asset exchange list actively trade classified level inactively trade asset classify level limited partnership represent investment private equity similar fund value general partner asset value unobservable input classify level follow table set forth retirement plan trust investment measure fair value december january quote price significant significant active unobserv market observable able identical asset input input level level level total asset dollar million shortterm investment fund government agency security debt instrument equity security commingle fund insurance contract asset trust investment fair value company benefit plan unfunded commingle fund level million million december january respectively million shortterminvestment fund level december fair value johnson johnson common stock directly hold plan asset million total plan asset december million total plan asset january level gain loss table set forth summary change fair value plan level asset year end december january equity commingled insurance dollar million debt instrument security fund contract asset total level balance january realize gain loss unrealize gain loss purchase sale issuance settlement net balance january realize gain loss unrealize gain loss purchase sale issuance settlement net balance december johnson johnson annual report saving plan company voluntary k saving plan design enhance exist retirement program cover eligible employee company match percentage employee contribution consistent provision plan heshe eligible total company match contribution plan million million million respectively capital treasury stock change treasury stock treasury stock amount million treasury stock share thousand share balance january employee compensation stock option plan repurchase common stock balance january employee compensation stock option plan repurchase common stock balance january employee compensation stock option plan issuance common stock associate acquisition synthes inc repurchase common stock balance december aggregate share common stock issue approximately share end cash dividend pay share compare dividend share share includes repurchase common stock associate acquisition synthes inc accumulate comprehensive income component comprehensive incomeloss consist follow total gain accumulate foreign gain loss currency loss employee benefit derivative comprehensive dollar million translation security plan hedge incomeloss january net change january net change january net change december amount accumulate comprehensive income present net relate tax impact foreign currency translation adjust income taxis relate permanent investment international subsidiary additional detail comprehensive income consolidated statement comprehensive income international currency translation translation subsidiary operate nonus dollar currency company determine local currency international subsidiary functional currency highly inflationary economy define compound cumulative rate inflation past year substantial portion cash flow local currency consolidate international subsidiary balance sheet currency effect record component accumulate johnson johnson annual report comprehensive income equity account include result translate balance sheet asset liability current exchange rate locate highly inflationary economy translation balance sheet account highly inflationary economy reflect operating result rollforward change foreign currency translation adjustment include note net currency transaction gain loss include income expense loss million million million respectively earning share follow reconciliation basic net earning share dilute net earning share fiscal year end december january january millions share amount basic net earning share attributable johnson johnson average share outstanding basic potential share exercisable stock option plan share repurchase treasury stock method convertible debt share accelerate share repurchase program adjust average share outstanding diluted diluted net earning share attributable johnson johnson dilute net earning share calculation include dilutive effect convertible debt offset relate reduction interest expense million aftertax year dilute net earning share exclude million million million share underlie stock option respectively exercise price option great average market value result antidilutive effect dilute earning share dilute earning share calculation fiscal year end december include dilutive effect million share relate accelerated share repurchase program associate acquisition synthes inc note consolidated financial statement additional detail increasedecrease volume weight average share price impact estimate approximately million share rental expense lease commitment rental space vehicle manufacture equipment office datum processing equipment operating lease approximately million million million respectively approximate minimum rental payment require operating lease initial remain noncancelable lease term excess year december dollar million total commitment capital lease significant common stock stock option plan stock compensation agreement december company stockbase compensation plan share outstanding contract company stock option plan longterm incentive plan longterm incentive plan scios inc stock option plan longterm incentive plan expire april option restrict share grant subsequent date longterm incentive plan compensation cost charge income plan million million million respectively total income tax benefit recognize income statement sharebase compensation cost million million million respectively total unrecognized compensation cost million million million respectively weight average period cost recognize year year year respectively sharebase compensation cost capitalize inventory insignificant periods johnson johnson annual report stock option stock option expire year date grant vest service period range month year option grant average high low price company common stock new york stock exchange date grant longterm incentive plan company issue million share common stock plus share cancel expire forfeit issue longterm incentive plan subsequent april share available future grant longterm incentive plan million end company settle employee stock option exercise treasury share previously treasury share replenish year number share settle employee stock option exercise pursuant accelerate stock repurchase agreement connection acquisition synthes inc company purchase common stock open market fiscal fourth quarter fair value option award estimate date grant blackschole option valuation model use assumption note follow table expect volatility represent blend rate year daily historical average volatility rate week average imply volatility rate base atthemoney trade johnson johnson option life year historical datum determine expect life option riskfree rate base treasury yield curve effect time grant average fair value option grant respectively fair value estimate base weighted average assumption riskfree rate expect volatility expect life year dividend yield summary option activity plan december january january change year end date present aggregate intrinsic weight value share thousand outstanding share average exercise price dollar million share january option grant option exercise option canceledforfeite share january option grant option exercise option canceledforfeite share january option grant option exercise option canceledforfeite share december total intrinsic value option exercise million million million respectively johnson johnson annual report follow table summarize stock option outstanding exercisable december share thousand outstanding exercisable average exercise average exercise exercise price range option average life price option price average contractual life remain year stock option exercisable january january average price average life year average price average life year respectively restrict share unit performance share unit company grant restrict share unit vest period year company grant performance share unit pay share johnson johnson common stock end threeyear performance period performance share unit vest vest tie achievement threeyear period equallyweighte goal directly align help drive longterm total shareholder return sale adjust operational earning share relative total shareholder return number share actually earn end threeyear period vary base actual performance target number performance share unit grant company settle employee stock issuance treasury share previously treasury share replenish year number share settle employee stock issuance pursuant accelerate stock repurchase agreement connection acquisition synthes inc company purchase common stock open market fiscal fourth quarter summary restrict share unit performance share unit activity plan december present outstanding restricted outstanding share thousand share unit performance share unit share january grant issue canceledforfeite share january grant issue canceledforfeite share january grant issue canceledforfeite share december average fair value restrict share unit grant respectively fair market value date grant fair value restrict share unit discount dividend pay restricted share unit vest period fair value restrict share unit settle million million million respectively johnson johnson annual report weight average fair value performance share unit calculate weighted average fair market value component goal date grant fair value sale earning share goal performance share unit estimate date grant fair market value share time award discount dividend pay performance share unit vest period fair value relative total shareholder return goal performance share unit estimate date grant monte carlo valuation model performance share unit issue johnson johnson annual report segment business geographic area sale customer dollar million consumer united states international total pharmaceutical united states international total medical device diagnostic united states international total worldwide total pretax profit identifiable asset dollar million consumer pharmaceutical medical device diagnostic total expense allocate segment general corporate worldwide total addition property depreciation plant equipment amortization dollar million consumer pharmaceutical medical device diagnostic segment total general corporate worldwide total johnson johnson annual report sale customer longlive asset dollar millions united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total note description segment company operate export sale significant company customer represent total revenue amount allocate segment include interest income expense noncontrolle interest general corporate income expense include expense billion billion currency relate expense relate acquisition synthes inc respectively general corporate include cash marketable security include million net litigation expense include product liability comprise million million pharmaceutical medical device diagnostic segment respectively include million inprocess research development expense comprise million million pharmaceutical medical device diagnostic segment respectively include million synthe integrationtransaction cost medical device diagnostic segment include million asset writedown adjustment comprise million million million pharmaceutical consumer medical device diagnostic segment respectively medical device diagnostic segment include million expense cost associate depuy asr hip program include million net litigation expense include product liability comprise million million pharmaceutical medical device diagnostic segment respectively include million net restructure expense comprise million expense medical device diagnostic segment gain million pharmaceutical segment medical device diagnostic segment include million expense cost associate depuy asr hip program include million net litigation gain include product liability expense comprise million expense pharmaceutical segment gain million medical device diagnostic segment medical device diagnostic segment include million expense cost associate depuy asr hip program longlive asset include property plant equipment net respectively intangible asset goodwill net respectively johnson johnson annual report select quarterly financial datum unaudite select unaudited quarterly financial datum year summarize second dollar million share datum quarter second q uarter q uarter fourth q uarter q uarter quarter q uarter fourth q uarter segment sale customer consumer pharmaceutical med device diagnostic total sale gross profit earning provision taxis income net earning attributable johnson johnson basic net earning share attributable johnson johnson dilute net earning share attributable johnson johnson quarter include aftertax gain million currency cost associate acquisition synthes inc second quarter include aftertax charge million asset writedown million net litigation million associate acquisition synthes inc million impairment inprocess research development quarter include aftertax charge million associate acquisition synthes inc million impairment inprocess research development million associate litigation include product liability million associate depuy asr hip program fourth quarter include aftertax charge million net litigation include product liability million associate acquisition synthes inc million associate depuy asr hip program million impairment inprocess research development quarter include aftertax charge million net litigation include product liability depuy asr hip program second quarter include aftertax charge million restructuring million litigation include product liability depuy asr hip program partially offset million aftertax gain associate adjustment value currency option relate acquisition synthes inc quarter include million aftertax charge associate adjustment value currency option deal cost relate acquisition synthes inc fourth quarter include aftertax charge million net litigation include product liability million cost associate depuy asr hip program million associate adjustment value currency option deal cost relate acquisition synthes inc business combination divestiture certain business acquire million cash stock million liability assume acquisition account purchase method accordingly result operation include financial statement respective date acquisition acquisition include synthes inc global developer manufacturer orthopaedic device guangzhou biosesal biotech co ltd developer biologic combination address moderate severe hemostasis angiotech pharmaceuticals inc intellectual property know related quilltm knotless tissueclosure device corlmmun inc developer phase ii treatment chf calibra medical inc developer unique wearable threeday insulin patch convenient discreet mealtime dose people diabetes multiple daily injection insulinspectrum vision llc service distributor contact lense serve russia facility ukraine kazakhstan marketing authorization trademark patent extend zyrtec relate market right australia canada johnson johnson annual report excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value iprd associate acquisitions corlmmun inc synthes inc iprd relate acquisition synthes inc million associate orthopaedic device iprd associate corlmmun million relate chf treatment iprd value calculate cash flow projection discount risk inherent project synthe inc probability success factor discount rate corlmmun probability success factor discount rate fiscal second quarter company complete acquisition synthes inc global developer manufacturer orthopaedic device purchase price billion cash stock net acquisition cost transaction billion base cash hand closing billion term agreement share synthes inc common stock exchange chf cash share johnson johnson common stock base calculate exchange ratio exchange ratio calculate june base relevant exchange rate closing price johnson johnson common stock date total fair value consideration transfer billion acquisition complete june base relevant exchange rate closing price johnson johnson common stock date total fair value consideration transfer billion janssen pharmaceutical company organize law ireland whollyowne subsidiary johnson johnson cash hand satisfy cash portion merger consideration stock portion merger consideration consist share johnson johnson common stock purchase janssen pharmaceutical bank pursuant accelerated share repurchase asr agreement date june june janssen pharmaceutical purchase aggregate approximately million share johnson johnson common stock initial purchase price billion asr agreement share deliver janssen pharmaceutical june final settlement transaction asr agreement expect occur half occur early option bank applicable later certain circumstance base theoretical settlement asr agreement additional million share issue settle asr agreement december addition company believe transactions asr agreement series relate internal transaction consummate tax efficient mannerin accordance applicable law possible internal revenue service assert contrary position challenge transaction tax perspective challenge total purchase price synthe share treat subject applicable tax approximately statutory rate company plus interest follow table summarize consideration transfer acquire synthes inc value acquisition date june dollar million cash multiply chf share synthe common stock outstanding exchange ratea common stock multiply share synthe common stock outstanding jj stock priceb total fair value consideration transfer synthe common stock outstanding million share acquisition date chfusd exchange rate b johnson johnson closing stock price new york stock exchange acquisition date share company finalize allocation purchase price individual asset acquire liability assume allocation purchase price include current period balance sheet base good estimate management assist management allocation company engage valuation specialist prepare independent appraisal certain estimate value surround litigation loss contingency finalize subject change finalize amount recognize obtain information necessary complete analysis expect finalize amount soon possible later year acquisition date follow table present amount recognize asset acquire liability assume acquisition date adjustment december johnson johnson annual report dollar millions june december cash cash equivalent inventory account receivable net current asset property plant equipment goodwill intangible asset noncurrent asset total asset acquire current liability defer taxis noncurrent liability total liability assume net asset acquire adjustment date acquisition account change inventory base result physical inventory count defer taxis reflect statutory tax rate apply intangible asset revision purchase price allocation material statement consolidated earning prior fiscal quarter asset acquire record medical device diagnostic segment acquisition synthes inc result billion goodwill goodwill primarily attributable synergy expect arise acquisition synthes inc goodwill expect deductible tax purpose purchase price allocation identifiable intangible asset include june december balance sheet follow dollar millions june december intangible asset definite live customer relationship patent technology total amortizable intangible trademark trade inprocess research development total intangible asset weight average life billion total amortizable intangible approximately year trade asset value determine indefinite life base number factor include trade history competitive environment market share future operating plan intangible asset definite life assign asset life range year majority intangible asset valuation relate customer relationship patent technology trade intangible asset company trauma cranio maxillofacial spine power tool business line additionally inprocess research development intangible asset value technology program unapprove product value iprd calculate cash flow projection discount risk inherent project discount rate apply johnson johnson annual report company process execute integration plan combine business sale organization system location result company continue incur integration cost operating result synthe report company financial statement begin june total sale net earning synthe fiscal year end december million million respectively follow table provide pro forma result operation fiscal year end december january synthes inc acquire january pro forma result include effect divestiture certain purchase accounting adjustment estimate change depreciation amortization expense acquire tangible intangible asset pro forma result include anticipate cost saving effect integration synthes inc accordingly amount necessarily indicative result acquisition occur date indicate occur future unaudited pro forma consolidated result dollar million share amount net sale net earning attributable johnson johnson dilute net earning share attributable johnson johnson company record acquisition relate cost million tax record cost product sell income expense connection synthe acquisition depuy orthopaedics inc agree divest certain right asset relate trauma business biomet inc complete initial closing transaction fiscal second quarter include country represent majority sale december transaction close worldwide certain business acquire million cash million liability assume acquisition account purchase method accordingly result operation include financial statement respective date acquisition acquisition include crucell nv global biopharmaceutical company focus research development production marketing vaccine antibodie infectious disease worldwide overthecounter brand jb chemicals pharmaceuticals limit include rinza russia lead multisymptom cough cold brand doktor mom russia number sell cough brand brand ownership johnson johnsonmerck consumer pharmaceutical co joint venture merck sharp dohme corp sterilmed inc leader reprocess remanufacture medical device excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value iprd associated acquisition crucell nv iprd relate acquisition crucell nv million associate vaccine antibodie prevent andor treat infectious disease value iprd calculate cash flow projection discount risk inherent project probability success factor range reflect inherent clinical regulatory risk discount rate apply fiscal second quarter company record charge billion intangible asset writedown billion impairment inprocess research development relate crucell business certain business acquire million cash million liability assume acquisition account purchase method accordingly result operation include financial statement respective date acquisition acquisition include acclarent inc privately hold medical technology company dedicate designing develop commercialize device address condition affect ear nose throat ent respivert ltd privately hold drug discovery company focus develop smallmolecule inhale therapy treatment pulmonary disease micrus endovascular llc global developer manufacturer minimally invasive device hemorrhagic ischemic stroke excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value iprd associate acquisitions acclarent inc respivert ltd johnson johnson annual report micrus endovascular llc iprd relate acquisition acclarent inc million associate novel endoscopic catheterbased devices meet need ent patient value iprd calculate cash flow projection discount risk inherent project probability success factor range reflect inherent clinical regulatory risk discount rate apply iprd relate acquisition respivert ltd million associate narrow spectrum kinase inhibitor unique profile antiinflammatory activity treatment moderate severe asthma chronic obstructive pulmonary disease copd cystic fibrosis cf value iprd calculate cash flow projection discount risk inherent project probability success factor range reflect inherent clinical regulatory risk discount rate apply iprd relate acquisition micrus endovascular llc million associate ischemic flow diverter technology value iprd calculate cash flow projection discount risk inherent project probability success factor range reflect inherent clinical regulatory risk discount rate apply exception synthes inc acquisition supplemental pro forma information accordance gaap standard relate business combination goodwill intangible asset provide impact aforementione acquisition material effect company result operation cash flow financial position company divestiture include bystolic nebivolol ip right forest laboratories inc trauma business depuy orthopaedics inc biomet inc therakos business affiliate gore capital partner iii lp sale certain consumer brand rhogam business gain divestiture business billion company divestiture include animal health business elanco division eli lilly monistat canada territory include puerto rico assets ortho dermatologics division subsidiary valeant pharmaceuticals international inc surgical instrument business codman shurtleff inc gain divestiture business billion company divestiture include breast care business ethicon endosurgery inc gain divestiture recognize incomeexpense net legal proceeding johnson johnson certain subsidiary involve lawsuit claim product liability intellectual property commercial matter governmental investigation legal proceeding arise time time ordinary course business company record accrual contingency probable liability incur loss reasonably estimate december company determine liability associate certain litigation matter probable reasonably estimate company accrue matter continue monitor related legal issue adjust accrual new information development accordance asc litigation regulatory matter currently disclose loss probable reasonably possible company unable determine estimate possible loss range loss amount accrue matter affect factor include damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute numerous party involve company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution report period matter aggregate material adverse effect company result operation cash flow period product liability certain subsidiary johnson johnson involve numerous product liability case damage claim substantial subsidiary confident adequacy warning instruction use accompany product issue feasible predict ultimate outcome litigation company establish product liability accrual compliance asc base currently available information case limit change accrual require future additional information available multiple product johnson johnson subsidiaries subject product liability claim lawsuit claimant seek substantial compensatory available punitive damage include levaquin asr xl acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system risperdal johnson johnson annual report pelvic meshes duragesicfentanyl patch topamax december approximately plaintiff direct claim pende lawsuit injury allegedly levaquin respect asr xl acetabular system depuy asr hip resurfacing system respect pinnacle acetabular cup system respect risperdal respect pelvic mesh respect duragesicfentanyl patch respect topamax august depuy orthopaedics inc depuy announce worldwide voluntary recall asr xl acetabular system depuy asr hip resurfacing system hip replacement surgery claim personal injury depuy johnson johnson number pende lawsuit continue increase case file federal court united states organize multidistrict litigation united states district court northern district ohio litigation file country outside united states primarily united kingdom canada australia company continue receive information respect potential cost associate recall fiscal fourth quarter company increase accrual depuy asr hip recall program relate product liability company complete analysis new information include number expect claim recently update revision rate recall product product liability expense case change accrual require future additional information available claim personal injury depuy johnson johnson relate depuy pinnacle acetabular cup system number pende product liability lawsuit continue increase company continue receive information respect potential cost anticipate number case case file federal court united states organize multidistrict litigation united states district court northern district texas company establish product liability accrual anticipation product liability litigation associate depuy pinnacle acetabular cup system change accrual require future additional information available claim personal injury ethicon inc ethicon johnson johnson arising ethicon pelvic mesh device treat stress urinary incontinence pelvic organ prolapse number pende product liability lawsuit continue increase company continue receive information respect potential cost anticipate number case case file federal court united states organize multidistrict litigation united states district court southern district west virginia addition class action individual personal injury case commence canada australia seek damage allege injury result ethicon pelvic mesh device company establish product liability accrual anticipation product liability litigation associate ethicon pelvic mesh product change accrual require future additional information available company believe ultimate resolution matter base historical reasonably likely future trend expect material adverse effect company financial position annual result operation cash flow resolution interim reporting period material impact company result operation cash flow period intellectual property certain subsidiary johnson johnson subject time time legal proceeding claim relate patent trademark intellectual property matter arise business significant matter describe patent infringement certain subsidiary johnson johnson involve lawsuit challenge coverage andor validity patent product subsidiary believe substantial defense challenge respect material patent assurance outcome matter loss case potentially adversely affect ability subsidiary sell product require payment past damage future royalty medical device diagnostic october tyco healthcare group lp tyco surgical corporation file lawsuit ethicon endosurgery inc ees united states district court district connecticut allege feature ees harmonic scalpel infringe tyco patent october motion summary judgment prior initial trial number claim find invalid number find infringe claim find valid infringe trial commence december court dismiss case prejudice ground tyco patent suit dismissal prejudice affirm appeal january tyco file complaint united states district court district connecticut assert infringement patent johnson johnson annual report previous lawsuit add new product tyco seek monetary damage injunctive relief case try july party await decision court october bruce saffran saffran file patent infringement lawsuit johnson johnson cordis corporation cordis united states district court eastern district texas allege infringement patent january jury return verdict find cordis sale cypher stent willfully infringe patent jury award saffran million march court enter judgment cordis million represent jury verdict plus million prejudgment interest cordis appeal judgment oral argument hear december decision court appeal pende company believe potential unfavorable outcome probable establish accrual respect case november roche diagnostic operations inc et al roche file patent infringement lawsuit lifescan inc lifescan united states district court district delaware accuse lifescan entire onetouch line blood glucose monitoring system infringement patent relate use microelectrode sensor september lifescan obtain favorable rule claim construction preclude find infringement court enter judgment roche july roche appeal court appeal reverse district court rule claim construction remand case district court new finding issue party await rule claim construction roche seek monetary damage injunctive relief june rembrandt vision technology lp rembrandt file patent infringement lawsuit johnson johnson vision care inc jjvc united states district court eastern district texas allege jjvc manufacture sale acuvueadvance acuvue oasys hydrogel contact lense infringe patent chang patent rembrandt seek monetary relief case transfer united states district court middle district florida jury return verdict hold accuse lense infringe patent rembrandt file appeal united states court appeal federal circuit november howmedica osteonics corp howmedica stryker ireland ltd stryker file patent infringement lawsuit depuy orthopaedics inc depuy united states district court district new jersey allege infringement depuy pinnacle acetabular cup system duraloc acetabular cup system patent relate duallocke mechanism feature acetabular cup system howmedica stryker seek monetary damage injunctive relief depuy file answer february file counterclaim assert stryker trident acetabular hip system infringe depuy patent depuy seek damage injunctive relief howmedica stryker medtronic minimed inc medtronic puerto rico operation co minime distribution corp collectively medtronic minime file patent infringement lawsuit animas corporation united states district court central district california allege animas onetouch ping glucose management system infringe patent medtronic minime seek monetary damage injunctive relief june depuy orthopaedics inc depuy file declaratory judgment action orthopaedic hospital oh united states district court northern district indiana seek declaration party right obligation patent right license agreement party relate development polyethylene material oh claim depuy owe royalty product antioxidant polyethylene depuy dispute owe royalty oh seek declaration court dispute contractual provision depuy file declaratory judgment action oh file separate suit subject matter united states district court central district california move consolidation california case pharmaceutical abbott biotechnology ltd abbott file patent infringement lawsuit centocor inc centocor janssen biotech inc jbi united states district court district massachusetts allege simponi infringe abbott patent nos salfeld patent abbott seek monetary damage injunctive relief april party participate arbitration issue jbi defense abbott equitably estop assert patent arbitrator reject jbi defense case reinstate district court fact discovery ongoing august abbott gmbh co abbott gmbh abbott bioresearch center file patent infringement lawsuit centocor jbi united states district court district massachusetts allege stelara infringe united states patent assign abbott gmbh jbi file complaint united states district court district columbia declaratory judgment noninfringement invalidity abbott gmbh patent complaint review patent interference decision grant priority invention asserted patent abbott gmbh case transfer district columbia district massachusetts trial hold september jury verdict favor centocor invalidate abbott patent claim posttrial briefing complete party await decision august abbott gmbh abbott laboratories limit bring patent infringement lawsuit federal court canada allege stelara infringe abbott gmbh johnson johnson annual report canadian patent trial schedule december canadian case addition canadian litigation august abbott file patent infringement lawsuit netherlands switzerland germany case abbott seek monetary damage injunctive relief litigation filer abbreviate new drug application anda follow summarize lawsuit pende generic company file abbreviate new drug application anda seek market generic form product sell subsidiary johnson johnson prior expiration applicable patent cover product anda typically include allegation noninfringement invalidity unenforceability patent event subsidiarie successful action statutory month stay expire united states district court ruling obtain thirdparty company involve ability approval united states food drug administration fda introduce generic version product issue result substantial market share revenue loss product concerta number generic company file anda seek approval market generic version concerta september settlement agreement enter kremersurban llc kudco ireland ltd collectively kudco pursuant kudco grant license patentinsuit market generic version concerta start july kudco obtain fda approval november alza corporation alza orthomcneiljanssen pharmaceuticals inc omjpi janssen pharmaceuticals inc jpi file patent infringement lawsuit united states district court district delaware impax laboratories inc impax teva pharmaceuticals usa inc teva pharmaceutical industries ltd collectively teva response impax teva file major amendment anda seek approval market generic version concerta expiration alza jpi patent relate concerta impax teva file counterclaim allege noninfringement invalidity alza jpi file second lawsuit teva response teva file second major amendment anda seek approval market additional dosage strength generic concerta product expiration alza jpi patent relate concerta case alza jpi seek order enjoin defendant market generic version concerta prior expiration alza jpi concerta patent september settlement agreement enter impax teva pursuant party grant license patentinsuit market generic version concerta start july early certain circumstance obtain fda approval ortho tricyclen lo number generic company file anda seek approval market generic version ortho tricyclen lo february jpi watson laboratories inc watson pharmaceuticals inc collectively watson enter settlement agreement pursuant settlement agreement party enter supply agreement jpi supply watson combinational oral contraceptive contain certain specify compound december early certain circumstance expiration patent december addition event watson wish exercise right supply agreement jpi grant watson license market watson anda product december early certain circumstance december january omjpi jpi file patent infringement lawsuit lupin ltd lupin pharmaceuticals inc collectively lupin united states district court district new jersey response lupin anda seek approval market generic version ortho tricyclen lo prior expiration jpi patent relate ortho tricyclen lo otclo patent lupin file counterclaim allege invalidity patent trial conclude june september court issue decision favor jpi particular court order effective date approval lupin anda previously approve early expiration otclo patent lupin appeal decision court appeal federal circuit oral argument hear february court decision pende november omjpi jpi file patent infringement lawsuit mylan inc mylan pharmaceuticals inc collectively mylan famy care ltd famy care united states district court district new jersey response famy care anda seek approval market generic version ortho tricyclen lo prior expiration otclo patent mylan famy care file counterclaim allege invalidity patent november jpi mylan enter settlement agreement pursuant mylan grant license otclo patent market generic version ortho tricyclen lo start december early certain circumstance obtain fda approval october jpi file patent infringement lawsuit sun pharma global fze sun pharmaceutical industry collectively sun united states district court district new jersey response sun anda johnson johnson annual report seek approval market generic version ortho tricyclen lo prior expiration otclo patent jpi file patent infringement lawsuit haupt pharma inc ranbaxy laboratories limited ranbaxy inc collectively haupt united states district court district new jersey response haupt anda seek approval market generic version ortho tricyclen lo prior expiration otclo patent december jpi haupt enter settlement agreement pursuant haupt grant license otclo patent market generic version ortho tricyclen lo start december early certain circumstance obtain fda approval august jpi file patent infringement lawsuit glenmark generics ltd glenmark generics inc usa collectively glenmark united states district court district new jersey response glenmark anda seek approval market generic version ortho tricyclen lo prior expiration otclo patent november settlement agreement enter glenmark pursuant glenmark grant license otclo patent market generic version ortho tricyclen lo start december early certain circumstance obtain fda approval case jpi seek seek order enjoin defendant market generic version ortho tricylcen lo expiration otclo patent prezista number generic company file anda seek approval market generic version prezista november tibotec inc tibotec llc tibotec pharmaceutical janssen rd ireland collectively tibotec file patent infringement lawsuit lupin ltd lupin pharmaceuticals inc collectively lupin mylan inc mylan pharmaceuticals inc collectively mylan united states district court district new jersey response lupin mylan respective anda seek approval market generic version tibotec prezista product expiration tibotec patent relate prezista lupin mylan file counterclaim allege noninfringement invalidity july tibotec file patent infringement lawsuit lupin united states district court district new jersey response lupin supplement anda add new dosage strength propose product august tibotec gd searle company gd searle file patent infringement lawsuit lupin mylan response notice letter advise anda seek approval market generic version tibotec prezista product expiration patent relate prezista tibotec exclusively license gd searle march tibotec gd searle file patent infringement lawsuit teva pharmaceuticals usa inc teva pharmaceuticals ltd collectively teva united states district court district new jersey response teva anda seek approval market generic version prezista expiration certain patent relate prezista tibotec own exclusively license gd searle march tibotec file patent infringement lawsuit hetero drugs ltd unit iii hetero usa inc collectively hetero united states district court district new jersey response hetero anda seek approval market generic version prezista expiration certain patent relate prezista tibotec exclusively license gd searle july agreement party court enter stay lawsuit pende final decision lawsuit teva respect validity andor enforceability patent tibotec license gd searle hetero agree bind final decision september court consolidate lawsuit lawsuit bring united states government defendant infringement united states governmentowne patent relate prezista purpose pretrial discovery trial proviso discovery complete party case deconsolidate trial june janssen products lp janssen rd ireland collectively janssen gd searle file patent infringement lawsuit lupin teva mylan united states district court district new jersey allege infringement newly issue united states reissue patent janssen exclusively license gd searle august janssen gd searle file patent infringement lawsuit lupin teva mylan united states district court district new jersey allege infringement newly issue united states reissue patent janssen exclusively license gd searle case consolidated lawsuit october janssen file motion file supplemental complaint lupin teva mylan united states district court district new jersey allege infringement united states patent nos mylan lupin teva lupin teva january court permit additional patent add consolidated action lawsuit tibotec janssen seek order enjoin defendant market generic version prezista expiration relevant patent johnson johnson annual report intellectual property matter september centocor ortho biotech products lp janssen product lp jplp intervene inventorship lawsuit file university kansas center research inc kucr united states america usa united states district court district kansas kucr allege kucr scientist add inventor usaowne patent relate velcade usa license patent foreign counterparts millennium pharmaceuticals inc mpi turn sublicense patent foreign counterpart jplp commercial marketing outside united states july party reach settlement agreement resolve dispute case submit inventorship issue arbitration outcome determine prespecifie payment kucr affect jplp right market velcade arbitration take place december decision favor kucr issue march result jplp require aforementioned prespecified payment kucr december state israel file lawsuit district court tel aviv jaffa omrix biopharmaceutical inc affiliate omrix lawsuit state claim employee governmentowned hospital inventor patent relate fibrin glue technology employee develop government employee state claim right transfer intellectual property omrix belong state state seek damage plus royalty quixil evicel product alternatively transfer patent state january genentech inc genentech initiate arbitration ucb celltech celltech seek damage allegedly cooperate centocor inc janssen biotech inc jbi improperly terminate prior agreement jbi sublicense genentech cabilly patent sell remicade jbi indemnity agreement celltech celltech assert jbi liable damage celltech require pay genentech arbitration follow arbitration hearing june arbitrator issue decision find liability celltech jbi liable potential indemnity claim jbi move recover attorney fee cost expense march noramco inc noramco move intervene patent infringement lawsuit file united states district court southern district new york sdny purdue pharma lp purdue noramco oxycodone customer impax laboratories inc impax teva pharmaceuticals usa inc teva amneal pharmaceuticals llc amneal february noramco appear behalf noramco customer watson laboratories inc florida andrx labs llc collectively watsonandrx similar lawsuit file purdue sdny lawsuit response defendant respective anda seek approval market generic extend release oxycodone product expiration certain purdue patent asserted patent relate oxycodone process make oxycodone noramco agree defend lawsuit behalf impax teva amneal watsonandrx noramco participate november trial lawsuit bring purdue noramco customer actavis elizabeth llc actavis take place active ingredient issue actavis lawsuit active ingredient issue lawsuit district court decision actavis case affect lawsuit decision district court actavis case pende august dr james swanson swanson file lawsuit alza corporation alza northern district california seek add inventor alzaowne patent relate concerta alternatively dr swanson allege patentsinsuit invalid andor unenforceable result alza allege omission dr swanson name inventor patent dr swanson seek damage award unjust enrichment alza file motion dismiss swanson claim oral argument schedule february government proceeding like company pharmaceutical medical device diagnostic industry johnson johnson certain subsidiary subject extensive regulation national state local government agency united states country operate result interaction government agency ongoing significant litigation bring investigation conduct government agency list possible criminal charge substantial fine andor civil penalty damage result government investigation litigation average wholesale price awp litigation johnson johnson pharmaceutical subsidiary jj awp defendant numerous pharmaceutical company defendant series lawsuit state federal court involve allegation pricing market certain pharmaceutical product amount fraudulent actionable conduct thing company allegedly report inflated average wholesale price awp drug issue payor allege awps calculate provider reimbursement level case federal action state action remove federal court consolidated pretrial purpose multidistrict litigation mdl johnson johnson annual report united states district court district massachusetts plaintiff case include class private person entity pay portion purchase drug issue base awp state government entity medicaid payment drug issue base awp june trial merit mdl court dismiss claim plaintiff class jj awp defendant march court dismiss claim class jj awp defendant prejudice awp case bring attorney general proceed trial manufacturer state case certain subsidiary johnson johnson settle include kentucky set trial january kansas set trial march louisiana mississippi set trial october illinois set trial alaska set trial july state case likely set trial course addition awp case jj awp defendant bring commonwealth pennsylvania try commonwealth court october november court find commonwealth favor regard certain claim pennsylvania unfair trade practice consumer protection law utpl enter injunction award million restitution million civil penalty court find jj awp defendant favor commonwealth claim unjust enrichment misrepresentationfraud civil conspiracy certain commonwealth claim utpl jj awp defendant appeal commonwealth court utpl rule pennsylvania supreme court company believe jj awp defendant strong argument support appeal company believe potential unfavorable outcome probable establish accrual respect verdict risperdal january janssen pharmaceutica inc janssen pharmaceutica janssen pharmaceuticals inc jpi receive subpoena office inspector general united states office personnel management seek document concern sale marketing payment physician connection sale marketing clinical trial risperdal document subsequent request department justice additional subpoena seek information marketing adverse reaction risperdal receive united states attorney office eastern district pennsylvania november numerous subpoena seek testimony witness grand jury receive jpi cooperate respond request document witness united states department justice united states attorney office eastern district pennsylvania government continue actively pursue criminal civil action february government serve civil investigative demand seek additional information relate sale marketing risperdal sale marketing invega focus matter allege promotion risperdal invega offlabel use government notify jpi pende qui tam action allege offlabel promotion risperdal government inform jpi intervene qui tam action file supersede complaint discussion resolve criminal penalty food drug cosmetic act relate promotion risperdal result agreement principle united states attorney office eastern district pennsylvania key issue relevant disposition criminal charge pursuant single misdemeanor violation food drug cosmetic act certain issue remain open settlement finalize company accrue amount cover financial component propose criminal settlement company reach agreement principle united states department justice settle pende civil false claim act matter pende eastern district pennsylvania concern sale marketing risperdal invega northern district california sale marketing natrecor discuss separately district massachusett allege defendant provide omnicare inc omnicare longterm care pharmacy rebate payment risperdal product discuss separately assume agreement finalize resolve federal government claim federal false claim act resolve pende state federal government litigation omnicare natrecor settle risperdal medicaidrelate claim state opt settlement tentative settlement agreement describe issue remain open resolve settlement finalize company accrue amount include additional accrual second quarter cover tentative settlement agreement settlement resolve pende state litigation matter risperdal state elect opt settlement extent state claim elect opt settlement company accrue equal state receive participate settlement state arkansas louisiana south carolina expect participate settlement discuss company believe strong argument appeal case company accrue equal state receive participate settlement addition attorney general multiple state include alaska arkansas louisiana massachusetts mississippi johnson johnson annual report montana new mexico south carolina utah pende action janssen pharmaceutica jpi seek follow remedy reimbursement medicaid public fund risperdal prescription write offlabel use compensation treat citizen allege adverse reaction risperdal civil fine penalty damage overpayment state violation state consumer fraud statute punitive damage relief relate alleged unfair business practice certain action seek injunctive relief relate promotion risperdal january jpi settle lawsuit file attorney general texas april lawsuit bring attorney general arkansas jury find jpi johnson johnson court impose penalty approximately billion jpi johnson johnson file appeal believe strong argument support appeal january court award attorney fee approximately million judgment appeal attorney general west virginia commence suit janssen pharmaceutica jpi base claim allege consumer fraud duragesic risperdal jpi find liable damage assess million jpi file appeal november west virginia supreme court reverse trial court decision december attorney general west virginia dismiss case relate risperdal payment jpi settle case insofar related duragesic attorney general louisiana file multicount complaint janssen pharmaceutica jpi johnson johnson later add defendant case try october issue try jury johnson johnson jpi violate state medicaid fraud act act misrepresentation allegedly mailing november dear health care professional letter risperdal jury return verdict jpi johnson johnson violate act award million damage trial judge subsequently award attorney general counsel fee expense million august interlocutory appellate court affirm judgment january louisiana supreme court accept johnson johnson jpi request appeal oral argument appeal set march office general counsel commonwealth pennsylvania file lawsuit janssenpharmaceutica jpi multicount complaint relate janssen pharmaceutica sale risperdal commonwealth medicaid program trial occur june trial judge dismiss case close plaintiff evidence commonwealth file appeal april july pennsylvania appeals court uphold dismissal commonwealth case attorney general south carolina file lawsuit johnson johnson janssen pharmaceutica jpi count march matter try liability time lawsuit limit claim violation south carolina unfair trade practice act include question johnson johnson jpi engage unfair deceptive act practice conduct trade commerce distribute november dear health care professional letter risperdal use product fdaapprove label jury find favor johnson johnson jpi june court award civil penalty approximately million jpi appeal judgment company believe strong argument support appeal oral argument appeal set south carolina supreme court march attorney general approximately state district columbia indicate interest pursue similar litigation jpi obtain tolling agreement stay run statute limitation pursue investigation jpi potential consumer fraud action connection marketing risperdal september jpi settle states district columbia nonmedicaid claim connection sale marketing risperdal invega total approximately million previously accrue company opinion ultimate resolution risperdal matter expect material adverse effect company financial position resolution reporting period material impact company result operation cash flow period omnicare september johnson johnson receive subpoena united states attorney office district massachusetts seek document relate sale marketing drug omnicare inc omnicare manager pharmaceutical benefit longterm care facility april johnson johnson certain pharmaceutical subsidiary serve civil qui tam case assert claim federal false claim act related state law claim allege defendant provide omnicare rebate allege kickback cause omnicare file false claim medicaid government program january government intervene case name johnson johnson orthomcneiljanssen pharmaceuticals inc janssen pharmaceuticals inc jpi johnson johnson health care systems inc defendant subsequently commonwealth massachusetts virginia kentucky states california indiana intervened action february united states district court district massachusetts dismiss qui tam case entirely dismiss case reject allegation defendant violate obligation report good price health care program official claim johnson johnson annual report united states individual state remain pende june party grant joint motion stay case pende resolution potential settlement discuss risperdal section november lawsuit file scott bartz employee united states district court eastern district pennsylvania johnson johnson certain pharmaceutical subsidiary jj defendant codefendant mckesson corporation mckesson omnicare inc february plaintiff file amend complaint jj defendant motion case transfer united states district court district massachusetts currently pende amend complaint allege variety cause action federal false claim act correspond state local statute include jj defendant engage improper transaction allegedly design report false prescription drug price federal government order reduce jj defendant medicaid rebate obligation complaint allege jj defendant improperly retaliate plaintiff raise allegation internally bartz seek multiple form relief include damage reinstatement position seniority status jj defendant subsequently move dismiss complaint march district court dismiss bartz claim federal false claim act decline exercise supplemental jurisdiction numerous relate claim state false claim act statute district court deny dismissal motion regard bartz claim retaliate violation federal false claim act violation new jersey conscientious employee protection act february party enter settlement agreement resolve bartz claim file joint motion dismiss lawsuit prejudice district court grant motion dismiss claim mcneil consumer healthcare start june mcneil consumer healthcare division mcneilppc inc mcneil consumer healthcare certain affiliate include johnson johnson company receive grand jury subpoenas united states attorney office eastern district pennsylvania request document broadly relate recall product mcneil consumer healthcare fda inspections fort washington pennsylvania lancaster pennsylvania manufacture facility certain document relate recall small number product subsidiary addition february government serve mcneilppc inc mcneilppc civil investigative demand seek record relevant investigation determine violation federal false claim act company cooperate united states attorney office respond subpoena company receive civil investigative demand multiple state attorney general office broadly relate mcneil recall issue company continue cooperate inquiry january oregon attorney general file civil complaint johnson johnson mcneilppc mcneil healthcare llc state court allege civil violation oregon unlawful trade practice act relate early recall mcneil otc product november state court grant motion company dismiss oregon complaint entirety prejudice december oregon file notice appeal court appeal state oregon march united states file complaint injunctive relief united states district court eastern district pennsylvania mcneilppc employee allege mcneilppc violation fda regulation manufacture drug facility operate lancaster pennsylvania fort washington pennsylvania las piedras puerto rico day party file consent decree permanent injunction resolve claim set forth complaint court approve enter consent decree march consent decree subject ongoing enforcement court require mcneilppc enhanced measure remediate facility fort washington facility voluntarily shut april remain shut thirdparty consultant certifie operation compliance applicable law fda concur thirdparty certification lancaster las piedras facility continue manufacture distribute drug provide party review manufacturing record select batch drug release facility certifie deviation review adversely affect quality select batch mcneilppc submit workplan fda remediation lancaster las piedras facility plan approve fda october thirdparty batch record review cease fda state facility appear compliance applicable law facility subject fiveyear audit period party facility deem fda apparent compliance applicable law july scios inc scio receive subpoena united states attorney office district massachusetts seek document relate sale marketing natrecor august scios advise investigation handle united states attorney office northern district california san francisco february qui tam complaint unseal united states district court northern district california allege thing improper activity promotion natrecor june united states government intervene qui tam action file complaint scios johnson johnson seek relief johnson johnson annual report federal false claim act assert claim unjust enrichment october criminal matter resolve civil case stay pende resolution potential settlement discuss risperdal section june johnson johnson receive subpoena united states attorney office district massachusetts relate marketing biliary stent cordis corporation cordis february government inform cordis closing investigation addition january complaint unseal united states district court northern district texas file kevin colquitt seek damage cordis party allege violation federal false claim act similar state law connection marketing biliary stents united states department justice state decline intervene january court grant cordis motion dismiss claim cordis prejudice plaintiff appeal september synthes inc synthe receive civil investigative demand issue pursuant false claim act united states attorney office eastern district pennsylvania demand seek information allegation fellowship offer hospital exchange agreement purchase product synthe produce document information response demand cooperate inquiry october european commission ec announce open investigation concern agreement janssencilag bv janssencilag sandoz bv relate supply fentanyl patch netherlands agreement infringe european competition law january ec issue statement objection set fact potential violation eu antitrust laws janssencilag prepare response statement objection april janssen pharmaceuticals inc jpi receive letter request certain document united states department justice relate marketing promotion doribax jpi provide document continue cooperate government inquiry acclarent inc acclarent receive subpoena united states attorney office district massachusetts request document broadly relate sale marketing promotion acclarent relieva stratus microflow spacer product acclarent cooperate united states attorney office respond subpoena august depuy orthopaedics inc depuy inc depuy synthes inc depuy synthes johnson johnson services inc receive informal request united states attorney office district massachusetts civil division united states department justice production material relate asr xl hip device government additional informal request production document device government investigate person entity submit cause submit false claim false statement affect federal health care program connection marketing use asr xl hip device depuy orthopaedics inc depuy synthes johnson johnson services inc voluntarily produce document response government informal request fully cooperate government civil investigation october johnson johnson contact california attorney general office multistate attorney general investigation market surgical mesh product hernia urogynecological purpose johnson johnson subsidiaries johnson johnson subsidiary enter tolling agreement state participate multistate investigation december therakos inc therakos subsidiary johnson johnson orthoclinical diagnostics inc ocd franchise receive letter civil division united states attorney office eastern district pennsylvania inform therakos united states attorney office investigate sale marketing uvadex methoxsalen uvar xts system period present united states attorney office request ocd johnson johnson preserve document relate investigation therakos subsequently acquire affiliate gore capital partner iii lp ocd johnson johnson retain certain liability result investigation activity occur prior sale therakos take appropriate step retain potentially relevant document cooperate united states attorney office investigation respect activity recent year johnson johnson receive numerous request variety united states congressional committee produce information relevant ongoing congressional inquiry policy johnson johnson cooperate inquiry produce request information general litigation start july lawsuit file united states district court district new jersey employer employee benefit plan fund seek recover amount pay risperdal plan participant general plaintiffs allege johnson johnson certain pharmaceutical subsidiary engage offlabel marketing risperdal violation federal new jersey rico statutes addition plaintiff assert state law claim case consolidate case seek class action status shortly action voluntarily dismiss december court dismiss action remain plaintiff april johnson johnson annual report plaintiff file new consolidated class action johnson johnson janssen lp janssen pharmaceuticals inc march action dismiss april plaintiff file notice appeal united states court appeal circuit appeal dismiss july april orthoclinical diagnostics inc ocd receive grand jury subpoena united states department justice antitrust division request document information period begin september present pertaining investigation allege violation antitrust law blood reagent industry ocd comply subpoena february ocd receive letter antitrust division indicate closed investigation november june follow public announcement ocd receive grand jury subpoena multiple class action complaint file ocd direct purchaser seek damage allege price fix case consolidate pretrial purpose united states district court eastern district pennsylvania blood reagent antitrust litigation august district court grant motion file plaintiff class certification ocd request interlocutory review class certification decision october appellate court grant ocd petition interlocutory review april putative class action lawsuit file united states district court northern district california representatives nursing home resident estate johnson johnson omnicare inc omnicare unidentified company individual february plaintiff file second amend complaint assert certain rebate agreement johnson johnson omnicare increase money spend pharmaceutical nursing home resident violate sherman act california business profession code second amend complaint assert claim unjust enrichment plaintiff seek multiple form monetary injunctive relief johnson johnson move dismiss second amend complaint march court grant motion entirety august dismiss claim assert plaintiff october court dismiss action prejudice plaintiff file notice appeal united states court appeals ninth circuit november february plaintiff stipulate voluntary dismissal matter prejudice pursuant term stipulation ninth circuit dismiss case entirety march start multiple complaint seek class action certification relate mcneil recall file mcneil consumer healthcare certain affiliate include johnson johnson united states district court eastern district pennsylvania northern district illinois central district california southern district ohio eastern district missouri consumer complaint allege generally purchaser mcneil medicine owe monetary damage penalty pay premium price defective medication expensive alternative medication complaint seek certification nationwide class purchaser medicine complaint harvey case seek certification class motrin ib purchasers missouri october judicial panel multidistrict litigation consolidated consumer complaint harvey case consolidate march lawsuit mcneil consumer healthcare et al marketing sale practice litigation pretrial proceeding united states district court eastern district pennsylvania january plaintiff case harvey case file consolidated amend civil consumer class action complaint cac name additional party claim july court grant motion johnson johnson dismiss cac prejudice permit plaintiff file amend complaint thirty day dismissal order august plaintiff file second amend civil consumer class action complaint sac july court grant johnson johnson motion dismiss sac prejudice separately september johnson johnson johnson johnson inc mcneil consumer healthcare division johnson johnson inc receive notice civil claim file nick field supreme court british columbia canada bc civil claim bc civil claim putative class action bring behalf person reside british columbia purchase period september present mcneil infant child overthecounter medicine manufacture fort washington facility bc civil claim allege defendant violate bc business practice consumer protection act canadian statute common law sell medicine allegedly safe andor effective comply canadian good manufacturing practice bc plaintiff serve affidavit support class certification april defendant respond affidavit serve june date hear certification application schedule september shareholder ronald monk file lawsuit united states district court district new jersey seek class certification allege johnson johnson certain individual include executive officer employees johnson johnson fail disclose number manufacture facility fail maintain current good manufacturing practice result price company stock decline significantly plaintiff seek pursue remedy securities exchange act recover allege economic loss december motion johnson johnson dismiss grant deny plaintiff move court reconsider december ruling defendant file answer remain claim amend complaint february case proceeding discoveryin court deny plaintiff motion reconsideration september plaintiff file second amend complaint johnson johnson move dismiss plaintiff second amend complaint april omj pharmaceuticals inc omj pr file lawsuit united states united states district johnson johnson annual report court district puerto rico allege overpayment federal income taxis tax year end november november omj pr allege internal revenue service erroneously calculate omj pr tax credit section tax code omj pr file motion summary judgment united states file cross motion summary judgment october court grant united states motion summary judgment deny omj pr motion summary judgment omj pr appeal decision omj pr lose lawsuit face liability subsequent tax year august arbitration panel rule mitsubishi tanabe pharma corporation tanabe janssen biotech inc jbi distributor remicade japan seek modify proportion net sale revenue tanabe remit jbi exchange distribution right commercial supply remicade supply price tanabe commence arbitration centocor ortho biotech inc jbi pursuant party distribution agreement grant tanabe right distribute remicade japan certain part asia jbi counterclaim increase supply price hearing hold november determine appropriate split revenue party await decision johnson johnson subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state local foreign law primary relief seek cost past andor future remediation shareholder derivative action start april number shareholder derivative lawsuit file united states district court district new jersey certain current director officers johnson johnson johnson johnson name nominal defendant action consolidate august lawsuit johnson johnson derivativelitigation additionally september shareholder derivative lawsuit file michael wolin new jersey superior court certain current director officers johnson johnson johnson johnson name nominal defendant action party action stipulate shall stay johnson johnson derivative litigation completely resolve shareholder derivative action similar claim collectively assert variety allege breach fiduciary duty include thing defendant allegedly engage approve fail remedy prevent defective medical device improper pharmaceutical rebate improper offlabel marketing pharmaceutical medical device product violation current good manufacturing practice regulation result product recall fail disclose aforementioned allege misconduct company filing securities exchange act complaint seek variety relief include monetary damage corporate governance reform johnson johnson move dismiss action ground inter alia plaintiff fail demand board director september johnson johnson derivative litigation dismiss prejudice leave file amend complaint johnson johnson file report johnson johnson derivative litigation matter july prepare special committee board director investigate allegation contain derivative action number shareholder demand letter board receive raise similar issue special committee assist investigation independent counsel special committee report recommend johnson johnson reject shareholder demand step necessary appropriate secure dismissal derivative litigation ii board director create new regulatory compliance committee charge responsibility monitor oversight company health care compliance quality compliance system issue board director johnson johnson unanimously adopt special committee recommendation april board director create regulatory compliance government affair committee august shareholder submit shareholder demand letter file shareholder derivative lawsuit united states district court district new jersey name current officer director defendant challenge board rejection demand november court consolidate case copeland v prince johnson johnson secure extension time respond complaint additional shareholder derivative lawsuit file united states district court district new jersey shareholder derivative lawsuit file new jersey superior court august name current director johnson johnson defendants johnson johnson nominal defendant complaints allege breach fiduciary duty relate company compliance foreign corrupt practice act participation united nations iraq oil food program company suffer damage result allege breach defendant fail disclose allege misconduct company filing securities exchange act plaintiff seek monetary damage state court plaintiff seek corporate governance reform federal lawsuit consolidate july jj fcpa derivative shareholder litigation amend consolidated complaint file august october johnson johnson move dismiss consolidated federal lawsuit ground plaintiff fail demand board director plaintiff secure extension time respond motion state lawsuit consolidate november jjshareholder johnson johnson annual report derivative litigation consolidate complaint file december january johnson johnson move dismiss stay state lawsuit pende resolution federal lawsuit move dismiss ground plaintiff fail demand board director court grant motion johnson johnson stay state lawsuit pende resolution jj fcpa derivative shareholder litigation july party shareholder derivative case pende federal court discuss specifically rejohnson johnson derivative litigation copeland v prince jj fcpa derivative shareholderlitigation file stipulation settlement permanently resolve action entirety october settlement approve court november notice appeal file united states court appeal circuit shareholder object approval settlement district court ground lawsuit settlement provide benefit company plaintiff counsel request excessive fee award june shareholder submit shareholder demand letter march new jersey building laborers annuity new jersey building laborer pension fund file additional shareholder derivative lawsuit new jersey superior court name current officer director defendant challenge board rejection demand shareholder derivative lawsuit purport allege claim subject settlement describe party action enter consent order stay action pende final approval settlement discuss november plaintiff agree voluntarily dismiss action september additional shareholder derivative lawsuit file united states district court district new jersey donovan spamer george leon family trust name current director director johnson johnson defendants johnson johnson nominal defendant lawsuit allege defendant breach fiduciary duty decision respect compensation chief executive officer period defendant misleading statement company annual proxy statement lawsuit voluntarily dismiss prejudice similar lawsuit behalf george leon family trust refile july lawsuit seek variety relief include monetary damage injunctive relief corporate governance reform settlement resolve potential claim board director evaluation allegation ongoing restructure cordis corporation subsidiary johnson johnson announce discontinuation clinical development program nevo sirolimuselute coronary stent cessation manufacture marketing cypher cypher select plus sirolimuselute coronary stent end company focus cardiovascular therapy significant patient need exist result mention restructuring plan announce cordis corporation company record million relate pretax charge approximately million pretax restructuring charge require cash payment million restructuring charge consist asset writeoff million million relate leasehold contract obligation expense million asset writeoff relate property plant equipment million intangible asset million inventory million record cost product sell cordis restructuring program substantially complete restructure charge record medical device diagnostic segment johnson johnson annual report report independent register public accounting firm shareholder board directors johnson johnson opinion accompany consolidated balance sheet relate consolidated statement earning statement comprehensive income statement equity statement cash flow present fairly material respect financial position johnson johnson subsidiaries december january result operation cash flow year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso company management responsible financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion financial statement company internal control financial reporting base integrated audits conduct audits accordance standard public company accounting oversight board united states standard require plan perform audits obtain reasonable assurance financial statement free material misstatement effective internal control financial reporting maintain material respect audits financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle company internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company ii provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate describe management report internal control financial reporting management exclude synthes inc assessment internal control financial reporting december acquire company purchase business combination exclude synthes inc audit internal control financial reporting synthes inc whollyowne subsidiary total asset total revenue represent approximately respectively relate consolidated financial statement amount year end december pricewaterhousecooper llp new york new york february johnson johnson annual report management report internal control financial reporting section sarbanesoxley act management require assess effectiveness company internal control financial reporting end fiscal year report base assessment company internal control financial report effective management company responsible establish maintain adequate internal control financial reporting company internal control financial reporting design provide reasonable assurance reliability company financial reporting preparation external financial statement accordance generally accept accounting principle internal control financial reporting matter design inherent limitation internal control financial reporting determine effective provide reasonable assurance respect financial statement preparation prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate company management assess effectiveness company internal control financial reporting december make assessment company criterion establish committee sponsor organization treadway commission coso internal control integrate framework criterion area control environment risk assessment control activity information communication monitoring company assessment include extensive documenting evaluating testing design operating effectiveness internal control financial reporting company acquire synthes inc consolidated subsidiary synthe june synthe total asset primarily intangible asset goodwill total revenue represent approximately respectively relate consolidated financial statement period end december acquisition occur june synthe previously subject requirement section sarbanesoxley act scope company assessment design effectiveness internal control financial reporting fiscal year exclude synthe exclusion accordance sec general guidance assessment recently acquire business omit scope year acquisition base company process assessment describe management conclude december company internal control financial report effective effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear alex gorsky dominic j caruso chairman board directors vice president finance chief executive officer chief financial officer johnson johnson annual report summary operation statistical data dollar million share amount sale customer sale customer international total sale cost product sell sell marketing administrative expense research development expense inprocess research development interest income interest expense net portion capitalize income expense net restructure earning provision taxis income provision taxis income net earning add net loss attributable noncontrolle interest net earning attributable johnson johnson percent sale customer dilute net earning share common stock percent return average shareholder equity percent increase decrease previous year sale customer dilute net earning share supplementary balance sheet datum property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding million basic diluted employee thousand attributable johnson johnson johnson johnson annual report shareholder return performance set forth line graph compare cumulative total shareholder return company common stock period year year end december cumulative total return standard poor stock index standard poors pharmaceutical index standard poors health care equipment index graph table assume invest december december company common stock standard poor stock index standard poors pharmaceutical index standard poors health care equipment index dividend reinveste year cumulative total shareholder return johnson johnson sp index sp pharmaceutical index sp healthcare equipment index johnson johnson annual report year cumulative total shareholder return johnson johnson sp index sp pharmaceutical index sp healthcare equipment index johnson johnson annual report exhibit subsidiary johnson johnson new jersey corporation domestic international subsidiary show december certain subsidiary international subsidiary name significant aggregate johnson johnson parent jurisdiction subsidiary organization subsidiaries acclarent inc delaware alza corporation delaware animas corporation delaware biosense webster inc california cna development llc delaware codman shurtleff inc new jersey cordis corporation florida cordis international corporation delaware cordis llc delaware depuy mitek hold corporation delaware depuy mitek llc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine llc ohio depuy synthes sales inc massachusetts depuy synthes inc delaware diabetes diagnostics inc delaware ethicon endosurgery inc new jersey ethicon endosurgery llc delaware ethicon llc delaware ethicon llc texas ethicon inc new jersey iso holding corp delaware jj holdings nevada inc nevada janssen alzheimer immunotherapy research development llc delaware janssen biotech inc pennsylvania janssen global services llc new jersey janssen oncology inc delaware janssen ortho llc delaware janssen pharmaceuticals inc pennsylvania janssen product lp new jersey janssen research development llc new jersey janssen scientific affairs llc new jersey janssen services llc new jersey janssen supply group llc pennsylvania janssencilag manufacturing llc delaware jjhc llc delaware jnj international investment llc delaware johnson johnson middle east inc new jersey johnson johnson consumer company inc new jersey johnson johnson development corporation new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson sales logistics company llc new jersey johnson johnson services inc new jersey johnson johnson urban renewal associate new jerseyjurisdiction subsidiary organization johnson johnson vision care inc florida jom pharmaceutical services inc delaware lifescan llc delaware lifescan products llc delaware lifescan inc california mcneil consumer pharmaceutical co new jersey mcneil healthcare llc delaware mcneil la llc delaware mcneil mmp llc new jersey mcneil nutritionals llc delaware mcneilppc inc new jersey mentor texas lp delaware mentor worldwide llc delaware micro typing systems inc florida micrus endovascular llc delaware middlesex assurance company limited vermont neutrogena corporation delaware nitinol development corporation california noramco inc georgia omj pharmaceuticals inc delaware omrix biopharmaceuticals inc delaware ortho biologics llc delaware orthoclinical diagnostics inc new york refresh holdings inc delaware rutan realty llc new jersey scios inc delaware sterilmed inc minnesota synthes usa products llc delaware synthes usa llc delaware synthes inc delaware anspach effort llc florida wellness prevention inc michigan international subsidiary almaco holding ag switzerland apsis france apsis germany gmbh germany beijing dabao cosmetics co ltd china berna biotech korea corporation korea republic berna rhein bv netherlands biosense webster israel ltd israel cilag advanced technologies gmbh switzerland cilag ag switzerland cilag gmbh international switzerland cilag holding ag switzerland cilag pharmaceuticals gmbh switzerland cordis francejurisdiction subsidiary organization cordis de mexico sa de cv mexico cordis europa nv netherlands cordis medizinische apparate gmbh germany corimmun gmbh germany crucell holland bv netherlands crucell nv netherlands crucell sweden ab sweden crucell switzerland ag switzerland depuy ireland ireland depuy france france depuy international holdings limited united kingdom depuy international limited united kingdom depuy medical private limited india depuy mitek sarl switzerland depuy motion sarl switzerland depuy orthopadie gmbh germany depuy uk holdings limited united kingdom ees holdings de mexico de rl de cv mexico ethicon france ethicon ireland ireland ethicon pr holdings ireland ethicon women health urology sarl switzerland ethnor farmaceutica sa venezuela fms future medical system sa switzerland gme healthcare bvba belgium high wycombe property management limit united kingdom jc general services cvba belgium janssen alzheimer immunotherapy ireland janssen alzheimer immunotherapy hold limited ireland janssen biologics ireland ireland janssen biologics bv netherlands janssen cilag farmaceutica sa argentina janssen de mexico de rl de cv mexico janssen inc canada janssen infectious diseasesdiagnostic bvba belgium janssen korea ltd korea republic janssen pharmaceutica nv belgium janssen pharmaceutical ireland janssen pharmaceutical holdings ireland janssen pharmaceutical kk japan janssen rd ireland ireland janssencilag france janssencilag ab sweden janssencilag ag switzerland janssencilag bv netherlands janssencilag farmaceutica ltda brazil janssencilag farmaceutica lda portugal janssencilag gmbh germanyjurisdiction subsidiary organization janssen cilag limited thailand janssencilag limited united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharma gmbh austria janssencilag pharmaceutical saci greece janssencilag pty ltd australia janssencilag spa italy janssencilag venezuela janssencilag sa spain janssencilag sa de cv mexico jc health care ltd israel jjc acquisition company bv netherlands johnson johnson china investment ltd china johnson johnson china ltd china johnson johnson hong kong limited hong kong johnson johnson ireland limited ireland johnson johnson new zealand limited new zealand johnson johnson philippines inc philippines johnson johnson proprietary limited south africa johnson johnson thailand ltd thailand johnson johnson ab sweden johnson johnson ag switzerland johnson johnson consumer thailand limited thailand johnson johnson consumer bv netherlands johnson johnson consumer holding france france johnson johnson consumer services eame ltd united kingdom johnson johnson de argentina sac e argentina johnson johnson de chile sa chile johnson johnson de colombia sa colombia johnson johnson de mexico sa de cv mexico johnson johnson de venezuela sa venezuela johnson johnson del ecuador sa ecuador johnson johnson del peru sa peru johnson johnson brasil industria e comercio de produtos para saude ltda brazil johnson johnson european treasury company ireland johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson gesellschaft mbh austria johnson johnson gmbh germany johnson johnson group holdings gmbh germany johnson johnson hellas commercial industrial sa greece johnson johnson holding gmbh germany johnson johnson inc canada johnson johnson industrial ltda brazil johnson johnson international financial services company ireland johnson johnson kk japan johnson johnson kft hungaryjurisdiction subsidiary organization johnson johnson korea sell distribution limited liability company korea republic johnson johnson korea ltd korea republic johnson johnson limitada portugal johnson johnson limited india johnson johnson limited united kingdom johnson johnson llc russian federation johnson johnson luxembourg finance company sarl luxembourg johnson johnson management limited united kingdom johnson johnson medical china ltd china johnson johnson medical pty limited south africa johnson johnson medical shanghai ltd china johnson johnson medical suzhou ltd china johnson johnson medical bv netherlands johnson johnson medical gmbh germany johnson johnson medical korea limited korea republic johnson johnson medical limited united kingdom johnson johnson medical mexico sa de cv mexico johnson johnson medical nv belgium johnson johnson medical products gmbh austria johnson johnson medical pty ltd australia johnson johnson medical sa argentina johnson johnson medical spa italy johnson johnson medical scs venezuela johnson johnson middle east fzllc united arab emirates johnson johnson pacific pty limited australia johnson johnson poland sp z oo poland johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson spa italy johnson johnson sdn bhd malaysia johnson johnson sihhi malzeme sanayi ticaret limited sirketi turkey johnson johnson swiss finance company limited united kingdom johnson johnson taiwan ltd taiwan johnson johnson vision care ireland ireland johnson johnson prodaja medicinskih farmacevtskih izdelkov doo slovenia johnson johnson sa spain johnson johnson sa de cv mexico johnson johnson sro czech republic latam international investment company ireland latam property holdings ireland lifescan scotland limited united kingdom mcneil ab sweden mcneil gmbh co ohg germany mcneil healthcare uk limited united kingdom mcneil manufacturing pty ltd australia mcneil products limited united kingdom mcneil sweden ab swedenjurisdiction subsidiary organization medo international sarl switzerland medos sarl switzerland mentor medical system bv netherlands mentor medical system cv netherlands obtech medical sarl switzerland omj ireland ireland omj pr holdings ireland omrix biopharmaceutical ltd israel orthoclinical diagnostic france orthoclinical diagnostic united kingdom orthoclinical diagnostic gmbh germany orthoclinical diagnostic kk japan orthoclinical diagnostic nv belgium pt johnson johnson indonesia indonesia shanghai johnson johnson pharmaceuticals ltd china synthe shanghai medical trading co ltd china synthe suzhou medical co ltd china synthes australia pty ltd australia synthes canada ltd canada synthes colombia sas colombia synthe deutschland hold gmbh germany synthe finanz ag switzerland synthes gmbh germany synthe gmbh switzerland synthes holding ag switzerland synthes industria e comercio ltda brazil synthes kk japan synthes limited united kingdom synthe lux finance srl luxembourg synthes lux hold srl luxembourg synthes luxembourg srl luxembourg synthes medical private limited india synthe produktions gmbh switzerland synthes srl italy synthes tuttlingen gmbh germany synthesstratec sa spain tasmanian alkaloid pty ltd australia tibotecvirco comm va belgium turnbuckle investment company ireland vania expansion france xianjanssen pharmaceutical ltd chinaexhibit consent independent register public accounting firm consent incorporation reference registration statement form form johnson johnson report date february relate financial statement effectiveness internal control financial reporting appear annual report shareholder incorporate annual report consent incorporation reference report date february relate financial statement schedule appear pricewaterhousecooper llp new york new york february exhibit certification chief executive officer pursuant section sarbanesoxley act alex gorsky certify review annual report fiscal year end december report johnson johnson company base knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report base knowledge financial statement financial information include report fairly present material respect financial condition result operation cash flow company period present report company certify officer responsible establish maintain disclosure control procedure define exchange act rule ae de internal control financial reporting define exchange act rules af df company design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report prepare b design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle c evaluated effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change company internal control financial reporting occur company recent fiscal quarter company fourth fiscal quarter case annual report materially affect reasonably likely materially affect company internal control financial reporting company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect company ability record process summarize report financial information b fraud material involve management employee significant role company internal control financial reporting alex gorsky chief executive officer date february exhibit b certification chief financial officer pursuant section sarbanesoxley act dominic j caruso certify review annual report fiscal year end december report johnson johnson company base knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report base knowledge financial statement financial information include report fairly present material respect financial condition result operation cash flow company period present report company certify officer responsible establish maintain disclosure control procedure define exchange act rule ae de internal control financial reporting define exchange act rules af df company design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report prepare b design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle c evaluated effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change company internal control financial reporting occur company recent fiscal quarter company fourth fiscal quarter case annual report materially affect reasonably likely materially affect company internal control financial reporting company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect company ability record process summarize report financial information b fraud material involve management employee significant role company internal control financial reporting dominic j caruso chief financial officer date february exhibit certification chief executive officer pursuant section sarbanesoxley act undersign alex gorsky chief executive officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifie good knowledge company annual report fiscal year end december report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company alex gorsky chief executive officer date february certification furnish sec report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend subject liability sectionexhibit b certification chief financial officer pursuant section sarbanesoxley act undersign dominic j caruso chief financial officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifie good knowledge company annual report fiscal year end december report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company dominic j caruso chief financial officer date february certification furnish sec report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend subject liability sectionexhibit cautionary statement pursuant private security litigation reformact safe harbor forward look statement company time time certain forwardlooking statement publiclyrelease material write oral forwardlooking statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement furthermore company undertake update forwardlooke statement result new information future event development important factor cause company actual result differ company expectation forwardlooke statement follow economic factor include inflation fluctuation interest rate currency exchange rate potential effect fluctuation revenue expense result margin competitive factor include technological advance achieve patent attain competitor new product introduce competitor challenge company patent competitor allegation company product infringe patent party potentially affect company competitive position ability sell product question require payment past damage future royalty particular generic drug firm file abbreviate new drug application seek market generic form company key pharmaceutical product prior expiration applicable patent cover product event company successful defending result lawsuit generic version product issue introduce result substantial market share revenue loss financial distress bankruptcy experience significant customer supplier impair ability case purchase company product pay product previously purchase meet obligation company supply arrangement change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage result prolong global economic downturn impact international operation financial instability international economy sovereign risk possible imposition governmental control unstable international government legal system interruption breach computer communication system include computer virus hack cyberattack impair company ability conduct business communicate internally customer result theft trade secret misappropriation asset compromise privacy sensitive information belong company customer business partner health care change country result pricing pressure include continued consolidation health care provider trend manage care health care cost containment shift government primary payer health care expense government law regulation relate sale promotion reimbursement pricing generally government law regulation affect international operation include relate security law compliance trade monetary fiscal policy taxis price control regulatory approval new product license patent right environmental protection conflict mineral possible drug reimportation legislation competition research involve development improvement new exist product process particularly significant result time time product process obsolescence developmentof new improved product important company success area business challenge difficulty inherent product development include potential inability successfully continue technological innovation complete clinical trial obtain regulatory approval united states internationally gain maintain market approval product possibility encounter infringement claim competitor respect patent intellectual property right preclude delay commercialization product significant litigation government action adverse company include product liability claim patent infringement claim antitrust claim increase scrutiny health care industry government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include limited debarment government business difficulty delay manufacture internally supply chain cause voluntary involuntary business interruption shutdown product shortage substantial modification business practice operation withdrawal suspension current product market possible civil penalty criminal prosecution product liability insurance product limit cost prohibitive unavailable product efficacy safety concern base scientific evidence result product withdrawal recall regulatory action fda international counterpart decline sale impact business combination include acquisition divestiture company externally pharmaceutical medical device diagnostic consumer industry change global climate extreme weather natural disaster affect demand company product service cause disruption manufacture distribution network alter availability good service supply chain affect overall design integrity company product operation reliance global supply chain production distribution process complex subject increase regulatory requirement adversely affect source supply pricing material product involve multiple party require significant capital expenditure subject lengthy regulatory approval possibility internal revenue service assert contrary position challenge transaction consummate connection acquisition synthes inc tax perspective challenge total purchase price synthe share treat subject applicable tax approximately statutory rate company plus interest impact political economic condition terrorist attack part world military action overseas instability financial market result terrorism military action issuance new revise accounting standard financial accounting standard board securities exchange commission foregoing list set forth factor impact company ability achieve result describe forwardlooke statement investor understand possible predict identify factor consider list complete statement potential risk uncertainty company identify factor list permit private security litigation reform act